

1 **Title: High-throughput cultivation of stable, diverse, fecal-derived microbial**  
2 **communities to model the intestinal microbiota**

3  
4 **Authors:** Andrés Aranda-Díaz<sup>1</sup>, Katharine Michelle Ng<sup>1</sup>, Tani Thomsen<sup>1</sup>, Imperio Real-  
5 Ramírez<sup>1</sup>, Dylan Dahan<sup>2</sup>, Susannah Dittmar<sup>1</sup>, Carlos Gutierrez Gonzalez<sup>3</sup>, Taylor  
6 Chavez<sup>1</sup>, Kimberly S. Vasquez<sup>2</sup>, Taylor H. Nguyen<sup>1</sup>, Feiqiao Brian Yu<sup>4</sup>, Steven K.  
7 Higginbottom<sup>2</sup>, Norma F. Neff<sup>4</sup>, Joshua E. Elias<sup>4</sup>, Justin L. Sonnenburg<sup>2,4</sup>, Kerwyn Casey  
8 Huang<sup>2,4\*</sup>

9  
10 <sup>1</sup>Department of Bioengineering, Stanford University, Stanford, CA 94305

11 <sup>2</sup>Department of Microbiology and Immunology, Stanford University School of  
12 Medicine, Stanford, CA 94305

13 <sup>3</sup>Department of Chemical and Systems Biology, Stanford University School of Medicine,  
14 Stanford, CA 94305

15 <sup>4</sup>Chan Zuckerberg Biohub, San Francisco, CA 94158

16

17 \*Correspondence: [kchuang@stanford.edu](mailto:kchuang@stanford.edu)

18

19 Lead author: Kerwyn Casey Huang, [kchuang@stanford.edu](mailto:kchuang@stanford.edu)

- 20    Keywords: *gut microbiota; ciprofloxacin; antibiotics; microbial ecology; culturomics; ex vivo;*
- 21    *synthetic communities; microbiota perturbations; ecological stability*

## 22 **Summary**

23 Mechanistic understanding of the impacts of the gut microbiota on human health has  
24 been hampered by limited throughput in animal models. To enable systematic  
25 interrogation of gut-relevant microbial communities, here we generated hundreds of *in*  
26 *vitro* communities cultured from diverse stool samples in various media. Species  
27 composition revealed stool-derived communities that are phylogenetically complex,  
28 diverse, stable, and highly reproducible. Community membership depended on both  
29 medium and initial inoculum, with certain media preserving inoculum compositions.  
30 Different inocula yielded different community compositions, indicating their potential  
31 for personalized therapeutics. Communities were robust to freezing and large-volume  
32 culturing, enabling future translational applications. Defined communities were  
33 generated from isolates and reconstituted growth and composition similar to those of  
34 communities derived from stool inocula. Finally, *in vitro* experiments probing the  
35 response to ciprofloxacin successfully predicted many changes observed *in vivo*,  
36 including the resilience and sensitivity of each *Bacteroides* species. Thus, stool-derived *in*  
37 *vitro* communities constitute a powerful resource for microbiota research.

## 38 **Introduction**

39 The gut microbiota is a diverse community that performs functions important for host  
40 physiology, including interactions with the immune system (Hooper et al., 2012),  
41 metabolism (Sonnenburg and Backhed, 2016), and the nervous system (Mayer et al.,  
42 2014). A wide range of environmental perturbations, including diet (Kashyap et al.,  
43 2013), antibiotics (Schubert et al., 2015), and osmotic diarrhea (Tropini et al., 2018), lead  
44 to changes in community composition and function. Human and animal models have  
45 enabled some mechanistic understanding of these responses. For example, gnotobiotic  
46 mouse models provide insights into particular microbial communities (Becker et al.,  
47 2011; Faith et al., 2011; Mark Welch et al., 2017; Reyes et al., 2013; Rezzonico et al., 2011;  
48 Turnbaugh et al., 2009) composed of a single species, a defined set of species, or of  
49 complex samples originating from specific hosts such as humans.

50

51 Importantly, our understanding of microbiota recovery from antibiotics is limited.  
52 Antibiotics disrupt colonization resistance and lead to pathogen expansion and fecal  
53 shedding (Barthel et al., 2003; Doorduyn et al., 2006; Lawley et al., 2008; Pavia et al.,  
54 1990; Stecher et al., 2007), and can affect host physiology, including changes in  
55 adiposity, insulin resistance, and cognitive function (Cho et al., 2012; Cox et al., 2014;  
56 Frohlich et al., 2016; Hwang et al., 2015). Understanding antibiotic effects across  
57 microbiotas, doses, and treatment regimens will assist in mitigating these adverse

58 effects. We recently showed, using mice colonized with human feces, that the  
59 microbiota shifts into a new, lower-diversity steady state after ciprofloxacin treatment,  
60 although certain taxa displayed a high level of resilience during recovery (Ng et al.,  
61 2019). It is unclear to what extent the response of each taxon can be predicted from its  
62 behavior in isolation; microbial interactions and drug modification can impact the  
63 efficacy of antibiotic treatment (Adamowicz et al., 2018; de Vos et al., 2017; Nicoloff and  
64 Andersson, 2016; Sanchez-Vizueté et al., 2015), which may underlie our current inability  
65 to explain individualized responses to fluoroquinolone treatment in humans  
66 (Dethlefsen and Relman, 2011) or to understand why some antibiotics, like vancomycin,  
67 negatively impact taxa known to be resistant to the drug *in vitro* (Ivanov et al., 2008).

68

69 *In vivo* investigations of the gut microbiota of humans and mice are limited in  
70 throughput, and it is often difficult to isolate and quantitatively tune the magnitude of  
71 perturbations. As a complementary approach, synthetic *in vitro* co-culturing of a  
72 defined community of isolated species has revealed key interspecies interactions and  
73 metabolic roles (de Vos et al., 2017; Gutierrez and Garrido, 2019; Kehe et al., 2019;  
74 Venturelli et al., 2018). However, such bottom-up approaches generally lack the  
75 complexity of typical gut microbiotas; further, microbes coexisting in a host shape each  
76 other's evolutionary paths (Barroso-Batista et al., 2020), which could underlie  
77 individualized responses of the human gut microbiota to antibiotics (Dethlefsen and

78 Relman, 2011). It is difficult to select a particular set of species to model complex  
79 ecosystems such as the mammalian gut without *a priori* knowledge of interspecies  
80 interactions; most approaches therefore choose representative species from the major  
81 taxa.

82

83 While sophisticated continuous-flow culture models (Macfarlane et al., 1998; Minekus et  
84 al., 1999; Van de Wiele et al., 2015) permit long time-scale experimentation and the  
85 manipulation of key environmental variables, these systems are also limited in  
86 throughput (to date, mini-bioreactor arrays have included 48 reactors running in  
87 parallel; (Auchtung et al., 2016). Other approaches to study the function of complex  
88 microbiotas *in vitro* include *ex vivo* resuspensions of stool or other natural communities  
89 in liquid media, for example to analyze drug metabolism by highly complex  
90 communities (Zimmermann et al., 2019). These approaches are higher throughput, but  
91 the extent to which they recapitulate the gut environment is not clear, and they have yet  
92 to be used to systematically study community assembly and growth from gut samples.  
93 In a recent study, diverse microbiomes from leaf and soil samples were passaged in  
94 minimal media with a single carbon source (Goldford et al., 2018). Batch culturing led to  
95 the selection of simple communities whose compositions were predictably governed by  
96 nutrient availability at the family but not the species level, revealing alternative species-

97 level community assembly patterns (Goldford et al., 2018). The extent to which these  
98 findings extend to human-relevant microbiotas and more complex media is unknown.

99

100 To close these gaps, here we established that top-down, stool-derived *in vitro*  
101 communities (SICs) are powerful tools for modeling responses of the gut microbiota to  
102 perturbations *in vivo*. We demonstrated that hundreds of SICs generated from distinct  
103 initial inocula in diverse media can be phylogenetically complex and diverse, and  
104 preserve the structure of the initial inoculum with generally stable and reproducible  
105 compositions. SICs can be frozen, grown in larger volumes, and reconstituted from  
106 isolates without affecting composition. Most importantly, upon antibiotic treatment,  
107 many of the responses of the SICs mimicked changes observed in the antibiotic-treated  
108 humanized gnotobiotic mice from which the initial inocula were sampled, indicating  
109 that SICs could be used to predict and interpret the results of *in vivo* experiments in  
110 high throughput.

111 **Results**

112

113 *Diet and antibiotic treatment provide a diverse pool of inocula*

114 To generate SICs in a straightforward, scalable, and reproducible manner, we focused  
115 on ex-germ-free mice colonized with human feces. These “humanized” mice facilitate  
116 controlled experimental manipulation within a mammalian host, enabling comparisons  
117 between *in vitro* and *in vivo* behaviors of communities of human commensals. We  
118 inoculated humanized mouse fecal samples into various media and repeatedly  
119 passaged in anaerobic batch cultures (Methods). We sought to inoculate with a set of  
120 fecal samples that varied widely in composition, yet were composed of the same set of  
121 members so that they could be readily compared.

122

123 We took advantage of our previous findings that diet and antibiotics have large,  
124 distinct, interacting effects on the composition of the microbiota (Ng et al., 2013;  
125 Sonnenburg et al., 2016). We inoculated 20 germ-free mice (5 per cage) with feces from a  
126 single human donor and allowed the microbiota to equilibrate for 6 weeks to allow for  
127 mucus normalization (Johansson et al., 2015). We shifted half of the mice (2 cages) from  
128 a standard diet (SD) to one deficient in microbiota-accessible carbohydrates (MD) and  
129 allowed the microbiota to re-equilibrate for two weeks. We then gavaged all mice (2  
130 cages SD, 2 cages MD;  $n=20$  total) for 5 days twice daily with 3 mg ciprofloxacin, which



131 inhibits bacterial type II topoisomerases such as *Escherichia coli* DNA gyrase. Since we  
132 previously showed that the responses of cage-mates to antibiotics are highly  
133 reproducible and stereotypical (Ng et al., 2019), we collected fecal samples from two  
134 randomly selected mice in different cages from each dietary condition on day 0 (pre-  
135 treatment) and on day 1 (peak of treatment, when the culturable load reached a  
136 maximum decrease of 10- to 100-fold (Ng et al., 2019)), day 5 (residual treatment, when  
137 ciprofloxacin was not being administered but was still detected in feces (Ng et al.,  
138 2019)), and day 14 (post-treatment) (Fig. 1A).

139

140 Using 16S sequencing and analysis (Methods), we quantified the relative abundances of  
141 amplicon sequence variants (ASVs, or unique sequences) and mapped them to taxa. SD  
142 mice underwent a substantial change in fecal-sample composition due to ciprofloxacin  
143 treatment, with consistent reductions in Bacteroidetes and Proteobacteria and  
144 expansions in Firmicutes and Verrucomicrobia at the peak of treatment (Fig. 1B, S1A).  
145 The relative abundance of the Bacteroidetes mostly returned to pre-treatment levels by  
146 day 5, while the Proteobacteria and Verrucomicrobia did not fully recover until day 14  
147 (Fig. 1B, S1A). Fecal samples from MD mice showed similar trends but had lower levels  
148 of Bacteroidetes throughout the experiment (Fig. 1B, S1A).

149

150 For SD mice, the number of uniquely detected ASVs (richness) dropped from 91 to 68

151 on day 1 of treatment and to 19 by day 5 (Fig. S1B). Post-treatment diversity partially  
152 recovered to 56 ASVs (Fig. S1B). Richness dynamics were qualitatively similar for MD  
153 mice (Fig. S1B).  
154  
155 Principal coordinates analysis (PCoA, Methods) indicated that microbiota trajectories  
156 were distinct between dietary conditions (Fig. 1C). Thus, feces from humanized mice  
157 fed distinct diets and sampled at different timepoints during antibiotics treatment  
158 yielded an array of qualitatively different inocula. All these inocula were derived from  
159 the same human donor sample, enabling the generation of SICs with distinct starting  
160 compositions but with the potential for overlapping ASVs, facilitating the assessment of  
161 culturing conditions on a common pool of microbes.

162

### 163 ***In vitro cultivation of stable SICs from fecal samples***

164 To generate SICs, we sampled mouse feces and quickly (<30 min after fecal pellet  
165 production) resuspended these 16 samples (2 diets, 4 treatment days, 2 mice per diet  
166 type) into media in anaerobic conditions and grew them in microplates in a plate reader  
167 at 37 °C (Methods, Fig. 1A). To explore multiple nutrient environments, we selected  
168 four common growth media: Brain Heart Infusion (BHI), Tryptone-Yeast extract-  
169 Glucose (TYG), Gifu Anaerobic Medium (GAM), and Yeast extract-Casitone-Fatty acids  
170 (YCFA). We inoculated three technical replicates of each resuspended fecal sample into

171 wells of each medium to test the replicability of the resulting SICs.

172

173 Nutrient supplies differ over time in the gut; hence, we grew SICs in anaerobic batch

174 culture rather than in a chemostat-like environment. Since some commensals require

175 >24 h to reach saturation (Tramontano et al., 2018), we allowed all cultures to grow for

176 48 h, before diluting them 200-fold into fresh medium. We repeated this cycle for 2-4

177 weeks (7-14 passages), and after each sub-culturing, we split the samples; half were

178 dedicated to glycerol frozen stocks and half to DNA extraction for 16S sequencing.

179 Passaged SICs were not frozen or exposed to oxygen at any point, and aside from the

180 brief period required for dilution, all samples were maintained at 37 °C throughout

181 passaging.

182

183 To determine whether SICs reached stable compositions, we first focused on 16S data

184 for the six SICs derived from pre-treatment samples from MD mice (Pre-MD) that were

185 grown in BHI. These samples underwent 16 passages rather than the typical 7, which

186 enabled us to identify whether changes in composition would occur over longer

187 timescales. At the family level, SICs stabilized by the second passage (Fig. 1D) and

188 retained most families from the original fecal sample (Fig. 1E). Of the families that were

189 present in the inoculum but not in the passaged SIC, most were at low abundance *in*

190 *vivo* (Fig. 1E); the lone exception was the Verrucomicrobiaceae, which were replaced by

191 Enterobacteriaceae in the SIC (Fig. 1D,E).

192

193 To quantify the relevance of SICs as a model for the gut microbiota, we introduced an  
194 SIC into germ-free mice. Families that were overrepresented *in vitro* receded *in vivo*,  
195 with family-level abundances similar to those of the humanized mice from which the  
196 SIC was derived (Fig. 1F, Fig. S1C). To evaluate effects on host physiology we  
197 quantified host and microbial proteins in the feces of three groups of mice: humanized  
198 mice, germ-free mice, and SIC-colonized mice. The host proteomes of SIC-colonized  
199 mice were more similar to those of humanized mice than to those of germ-free mice,  
200 and immunoglobulins were upregulated after colonization in SIC-colonized mice (Fig.  
201 S1D). In the SIC metaproteome, proteins from two of the most abundant bacterial  
202 species (determined via 16S sequencing) were present at levels similar to those in SIC-  
203 colonized and humanized mice (Fig. S1E). These findings demonstrate that top-down *in*  
204 *vitro* cultivation from fecal samples can deterministically select complex SICs that are  
205 stable under passaging for several weeks; re-introduction of SICs into a host re-  
206 establishes gut microbiota composition and promotes host homeostasis.

207

208 A previous soil and plant microbiota passaging study reported that despite  
209 convergence at the family level, genus-level composition was highly divergent across  
210 technical replicates (Goldford et al., 2018). In our experiments, family-level dynamics

211 were similar across all three replicate SICs from each of the two mice (Fig. S1F), as  
212 confirmed via PCoA (Fig. S1G). To test whether family-level replicability extended to  
213 the ASV level, we calculated the pairwise correlation coefficients of  $\log_{10}$ (relative  
214 abundance) between 7th passages of the 3 technical replicates of the SIC in Fig. 1D.  
215 Correlation coefficients and the percentage of ASVs shared (above 0.1% in both  
216 replicates) were uniformly high (Fig. 1G,H), and all ASVs that were present in only one  
217 replicate had relative abundance <1%. The three replicates contained 50 ASVs in total at  
218 >0.1%, which we define as a conservative measure of detectability, of which 14% were  
219 shared by exactly two replicates and 70% were shared by all three replicates. The 35  
220 shared ASVs belonged to 9 families, 6 classes, and 3 phyla, and accounted for  $97.5 \pm 1.1\%$   
221 (mean  $\pm$  standard deviation) of SIC total abundance. Hence, SIC replicability extends  
222 even to individual ASVs.

223  
224 SICs were also reproducible across media and inocula (Fig. S1H, Supplementary Text).  
225 The lowest reproducibility was within SICs cultured in GAM and YCFA (Fig. S1I),  
226 where the dominance or absence of the Enterococcaceae explained most of the variation  
227 (Fig. S1J, Supplementary Text). Complex synthetic media mainly composed of amino  
228 acids and simple carbohydrates also drove the composition of SICs to be dominated by  
229 Enterococcaceae or Enterobacteriaceae (Fig. S1K). These findings indicate that *in vitro*  
230 culturing can lead to the selection of a few species in some media, and that SICs are

231 sometimes stochastic, even in media such as YCFA that promote the growth of many  
232 commensals in isolation. These data also show that the SICs are generally diverse and  
233 reproducible in BHI and TYG.

234

235 For steady-state SICs derived from feces to be useful for further experimentation, they  
236 would ideally maintain their composition after freezing, and during growth in larger  
237 volumes and without shaking. We inoculated the frozen stock from the 7<sup>th</sup>-passage SIC  
238 in Fig. 1D (the last passage for which all other SICs in this work had frozen stocks, and a  
239 passage in which all BHI communities had achieved stability, Fig. S1L) and grew it in a  
240 15-fold larger volume (3 mL) of BHI in glass test tubes without shaking. The tube-  
241 grown SIC had similar composition as the shaken SIC grown in a 96-well plate (Fig. 1I).  
242 Thus, shaking is not required, allowing a large number of plates to be grown in an  
243 incubator simultaneously, and large cultures can be readily produced.

244

245 To test SIC robustness to freezing, we inoculated -80 °C frozen stocks of the 3 mL test-  
246 tube cultures directly into fresh BHI and passaged them for three additional 48-h cycles.  
247 A single passage was sufficient to re-establish a composition closely matching that of  
248 the 7<sup>th</sup> passage pre-freezing (Fig. 1J); 37 of 50 ASVs at >0.1% were retained and  
249 accounted for 94.6% of the relative abundance pre-freezing. The composition was  
250 unchanged after two additional passages (Fig. S2). All other tested communities grown

251 in BHI from other fecal inocula behaved similarly (Fig. S2), indicating that most taxa are  
252 preserved during freezing and thawing and that there were no substantive differential  
253 effects of freezing across taxa. Hence, SICs can be grown across a range of volumes,  
254 frozen, and revived without impact to the composition.

255

### 256 *Initial inoculum composition and nutrient conditions affect SIC composition*

257 To determine how quickly SICs converge, we computed the weighted Unifrac distance  
258 in ASV abundances (Methods) and determined when the distance decreased below 0.15  
259 (the mean weighted Unifrac distance between technical replicates at the third passage).

260 While a few SICs with low replicability also exhibited longer convergence timescales,  
261 the vast majority converged to a steady state within 4 passages (Fig. S1L).

262

263 To determine the extent to which the abiotic environment and inoculum dictated  
264 steady-state SIC compositions after 7 passages, we performed PCoA of our 16S data for  
265 all passages of all SICs in all media. The first coordinate was largely determined by the  
266 presence or absence of several co-occurring families, including Enterobacteriaceae (Fig.  
267 S3A). Most of these families were present in the pre-treatment inocula and were  
268 undetectable in residual treatment (day 5) inocula (Fig. S3B), suggesting that most of the  
269 variation is explained by the fecal inocula, not the culture media. Similar to previous  
270 studies of communities inoculated from soil and leaf samples (Goldford et al., 2018), our

271 data approximately clustered in the space of the first two principal coordinates  
272 according to culture media; BHI and TYG SICs overlapped but were well separated  
273 from GAM and even more so from YCFA (Fig. 2A). BHI, TYG, and GAM SICs were  
274 more similar to their inocula than YCFA SICs when using a weighted approach that  
275 accounts for taxonomical relative abundances (Fig. 2B). Using presence and absence of  
276 taxa as a measure of similarity (thus giving more weight to low-abundance taxa), BHI  
277 and TYG are better mimics of the conditions that produced the fecal pellet (Fig. 2A),  
278 regardless of the inoculating composition. The data also clearly clustered according to  
279 the time during antibiotic treatment when the inocula were sampled (Fig. 2A). Some  
280 SICs derived from the peak of antibiotic disturbance exhibited the largest differences  
281 from starting inoculum (Fig. 2A,C); instead, they more closely resembled SICs derived  
282 from residual treatment samples (Fig. 2A), likely due to low viable counts from samples  
283 at the peak of ciprofloxacin disturbance (Ng et al., 2019), implying that after antibiotic  
284 treatment, a fecal sample contains many non-viable cells. The direction separating  
285 clusters of sampling time was approximately orthogonal to the direction separating  
286 SICs by medium (Fig. 2A), indicating that both the availability of taxa in the inoculum  
287 and the ability of those taxa to grow as communities in a given medium dictate the  
288 composition of SICs.

289

290 *SIC and fecal-sample richness are highly correlated due to maintenance of abundant*



291 *species and within-family replacement*

292 The presence or absence of multiple families in the first principal coordinate, and the  
293 observation that this coordinate mainly separated SICs by their inocula (Fig. 2A),  
294 suggested that SIC richness depends on the richness of the inoculum. Indeed, the first  
295 principal coordinate was correlated with inoculum richness (Fig. S3C), and the richness  
296 of SICs grown in BHI, TYG, and GAM was highly correlated with that of the inoculum,  
297 with some SICs having >50 detectable ASVs (Fig. 2D). These SICs showed similar  
298 evenness (relative abundance homogeneity) as their inocula (Fig. S4A). SICs grown in  
299 YCFA exhibited very low diversity and extreme evenness (Fig. 2D, S4A).

300

301 The total number of ASVs present in at least one inoculum was 158, and the total  
302 number of ASVs present in at least one SIC was 117. Nevertheless, only 79 of the 158  
303 ASVs (50%) present in the inocula were present in at least one SIC, indicating  
304 emergence of some ASVs from below the limit of detection (Supplementary text). Most  
305 of the retained ASVs (68 of 79) were present in at least one BHI SIC. While fecal  
306 diversity was approximately maintained in SICs (Fig. 2D) and family-level composition  
307 was preserved for families conducive to culturing (Fig. 1D, 2A), passaging led to a  
308 reproducible decrease of some ASVs to below the limit of detection; this decrease was  
309 biased toward ASVs that started at lower abundance and was mostly balanced by  
310 emergent ASVs from the same family (Supplementary text). The only family to emerge

311 above the limit of detection during passaging was the sole Gammaproteobacterial  
312 family (an Enterobacteriaceae). Nonetheless, the Enterobacteriaceae emerged almost  
313 exclusively in SICs derived from pre- and post-treatment inocula (Fig. S1M), indicating  
314 that this emergence was not due to contamination. Thus, both maintenance and within-  
315 family replacement contribute to SIC richness at steady state.

316

### 317 *SIC growth dynamics reflect compositional characteristics*

318 We speculated that SIC characteristics such as richness and the presence or absence of  
319 key species may be reflected in the features of continuous growth curves. We first  
320 focused on BHI SICs since they harbored the highest diversity (Fig. 2D). We measured  
321 SIC optical densities (ODs) at 20 h (“yield”) because by that time all growth rates had  
322 become virtually zero. We averaged the last 4 passages for each condition and sample  
323 and found a range of mean final ODs that were highly correlated with SIC richness  
324 ( $R=0.92$ ,  $p=6\times 10^{-30}$ ; Fig. 2E). Similar relationships held for TYG and GAM (Fig. S5A).  
325 Thus, the yield of these SICs was greater when more taxa are present, suggesting that in  
326 the appropriate medium, SICs with low diversity could support the growth of more  
327 taxa if they were present in the inoculum.

328

329 We next calculated the maximum growth rate (Methods) for each SIC and again  
330 observed that richness correlated with maximum growth rate ( $R=0.50$ ,  $p=2.7\times 10^{-4}$ , Fig.

331 S5B). The distribution of maximum growth rates was bimodal, reaching as high as 1.7 h<sup>-1</sup>  
332 (doubling time ~25 min) (Fig. S5B), similar to the growth rates of fast-growing species  
333 such as *E. coli* in rich media (Baev et al., 2006). We hypothesized that the presence of  
334 those families would correlate with SIC maximum growth rate. The summed relative  
335 abundance of the two families ( $f_{\text{Enteroc}}$ ) was also bimodal and correlated with maximum  
336 growth rate (Fig. S5C). SICs with  $f_{\text{Enteroc}} > 20\%$  had a significantly higher maximum  
337 growth rate (Fig. 2F). Yield (Methods) was also linked to the presence of  
338 Enterobacteriaceae and Enterococcaceae after 48 h of growth (Fig. 2G). These  
339 correlations were similar in TYG and GAM (Fig. S5D), indicating that the relationship  
340 between these families and growth rate is likely medium-independent.

341  
342 In YCFA, there was no correlation between richness and final OD (Fig. S5A), probably  
343 due to the overall low diversity of these SICs. Nonetheless, the relative abundance of  
344 fast growers was still linked to maximum growth rate (Fig. S5D). Some YCFA technical  
345 replicates that diverged in composition during passaging exhibited blooming of an  
346 *Enterococcus* species in the sixth passage in two of three replicates (Fig. S1Jiii). This  
347 bloom coincided with a change in maximum growth rate (Fig. 2H,I), suggesting that  
348 growth features can also be used to dynamically detect major changes in composition *in*  
349 *vitro*.

350

351 *The population growth behavior of SICs can be partially reconstituted using isolates*

352 Ideally, our top-down approach to SIC cultivation could be complemented with  
353 bottom-up reconstitution using isolates. We focused on an SIC cultured in BHI from a  
354 MD mouse pre-treatment (Pre-MD) inoculum (parent SIC, Fig. 1D,3A) based on its high  
355 diversity (>50 ASVs, Fig. 2D). We obtained 15 distinct isolates by plating and analyzing  
356 192 colonies (Fig. 3A, Methods). While these isolates represented <30% of the total  
357 number of ASVs in the parent SIC, they accounted for 69% of its total abundance (Fig.  
358 3B). Our isolates included the sole Enterococcaceae, Porphyromonadaceae, and  
359 Enterobacteriaceae ASVs present at >0.1% in the parent SIC (Fig. 3B).

360

361 To test whether these 15 isolates were sufficient to recapitulate the growth and  
362 composition of the parent SIC, we examined the growth behaviors of our parent SIC, as  
363 well as the isolates alone and in a reconstituted SIC (Fig. 3A). We grew each isolate from  
364 frozen stock in the medium from which it was isolated at 37 °C for 48 h. We then  
365 passaged the isolates individually in BHI and measured OD over time to quantify lag  
366 time, maximum growth rate, and yield. *Enterococcus* and *Escherichia* strains had higher  
367 maximum growth rates and shorter lag times than the other isolates (Fig. 3C,D), and  
368 were relatively abundant in the parent SIC ( $7.6\pm 0.8\%$  and  $15.1\pm 0.1\%$ , respectively;  $n=3$ ,  
369 Fig. 3B). While the initial phase of growth after subculturing is likely dominated by  
370 these fast-growing species, the parent SIC grew significantly slower than the three

371 *Enterococcus* isolates (all of which were represented by the same ASV) and *Escherichia*  
372 *fergusonii* (Fig. S6A); the lag time of the parent SIC was higher than the shortest isolate  
373 lag time (*E. fergusonii*) (Fig. S6B). Isolate yield was more homogeneous (Fig. 3E).  
374 Although some of the poorest growers were *Bacteroides thetaiotaomicron* and  
375 *Parabacteroides distasonis* (final ODs  $0.032 \pm 0.004$  and  $0.010 \pm 0.006$ , respectively, Fig. 3C),  
376 the corresponding ASVs ended up as  $13.23 \pm 0.6\%$  and  $1.7 \pm 0.1\%$  of the parent SIC,  
377 respectively, suggesting that their growth is not greatly hampered by the initial  
378 expansion of other species.

379  
380 We built a reconstituted SIC (Fig. 3A) by growing the 15 isolates independently to  
381 saturation, diluting them to OD=0.001 in BHI, and mixing them in equal volumes. To  
382 test whether other strains slowed the growth of *Enterococcus* spp. and *E. fergusonii* in the  
383 parent SIC, we monitored growth at 37 °C for 48 h and then passaged this reconstituted  
384 SIC twice more. The reconstituted SIC had a higher maximum growth rate but the same  
385 lag time as its parent SIC in the third passage (Fig. 3F, S6C). Thus, fast-growing species  
386 likely expand initially in the absence of competition for nutrients, reshaping the niche  
387 landscape, after which slower-growing species fill unoccupied or new niches and  
388 enforce physiological states on the fast-growing species that make them unable to grow  
389 as quickly in subsequent passages despite their higher relative abundance. Supporting  
390 this notion, the yield of the parent SIC was higher than that of the reconstituted SIC in

391 the third passage (Fig. 3G); this increase was realized during entry to stationary phase  
392 (Fig. S6D), indicating that the other, unisolated species were slow growers that occupy  
393 niches not filled by the isolates. Both sets of species contribute to yield and further  
394 depress maximum growth rate.

395

396 Are the growth properties of reconstituted SICs general to the component species or  
397 specific to isolated strains? We built an SIC with the closest relatives of each of the 15  
398 isolates that were available in reference strain collections (reference SIC, Fig. 3A) and  
399 monitored growth of the reference strains for one passage and of the reference SIC for  
400 three passages. The maximum growth rate of the isolates and their closest relative  
401 reference strains grown alone were highly correlated (Fig. S6E); the reference SIC had  
402 the same maximum growth rate (Fig. 3E) and a longer lag phase (Fig. S6C) than the  
403 reconstituted SIC. However, the reference SIC yield was substantially lower than that of  
404 the reconstituted SIC and the parent SIC (Fig. 3G), likely because *E. fergusonii* had the  
405 highest yield of all isolates but the corresponding reference strain exhibited a much  
406 lower yield in BHI (Fig. 3H). Hence, the ability of co-cultures to recapitulate a complex  
407 SIC can depend on community effects (growth rate) and metabolic properties of  
408 individual strains (yield).

409

410 To test how much the composition of reconstituted and reference SICs resembled that of

411 the parent SIC, we performed 16S amplicon sequencing (Methods). The reconstituted  
412 and reference SICs mostly stabilized within one passage (Fig. 3I). In general, the relative  
413 abundances of the ASVs in the reconstituted and reference SICs were highly correlated  
414 with those in the parent SIC (Fig. 3J,K), but not with isolate yields or maximum growth  
415 rates (Fig. 3L,M). The family-level relative abundances in reconstituted and reference  
416 SICs were correlated (Fig. S6F). Notably, even though *E. fergusonii* and *Enterococcus* spp.  
417 can grow more quickly and more than most other isolates (Fig. S6E), their overall  
418 contributions to co-culture yield were limited by the other species. Moreover, the  
419 similarly high abundances of the 3 *Bacteroides* species (despite all but *B. fragilis* being  
420 poor growers in isolation in unsupplemented BHI, Fig. S6E) suggests that some  
421 *Bacteroides* rely on other organisms for optimal growth. Overall, co-culturing these 15  
422 species seems to reproduce much of the metabolic web responsible for establishing their  
423 abundances in the parent SIC.

424

#### 425 *Ciprofloxacin alters SICs in a manner generally consistent with isolate sensitivities*

426 We queried the responses of our SICs to ciprofloxacin. We selected an SIC derived from  
427 an inoculum that had not been exposed to the drug *in vivo* (pre-treatment from SD  
428 mouse, Pre-SD, Fig. 4A). We grew a frozen stock in BHI for 48 h over two rounds of  
429 passaging and then diluted 1:200 into a 96-well plate in duplicate with increasing  
430 ciprofloxacin concentrations (Fig. 4Ai). The maximum growth rate of the SICs decreased

431 monotonically with drug concentration (Fig. 4B) and the collective minimum inhibitory  
432 concentration (MIC) for the SIC was  $>32 \mu\text{g/mL}$  (Fig. 4B). The final OD of the Pre-SD  
433 SIC exhibited at least two notable decreases, at the lowest and highest concentrations  
434 (Fig. 4B); our findings (Fig. 2A) suggest that these decreases are due to drops in  
435 diversity. To test the effects of long-term exposure to ciprofloxacin, we passaged the  
436 Pre-SD SICs in BHI with the ciprofloxacin concentrations to which they were exposed in  
437 the first passage for two more *in vitro* passages (Fig. 4Aii,iii). For the highest  
438 concentrations, the maximum growth rate increased moderately after the first passage  
439 (Fig. 4C). The increasing growth rate upon additional passages in antibiotic suggest that  
440 the structure of the SIC changes after *in vitro* treatment, potentially due to selection of  
441 resistant subpopulations.

442

443 To assess compositional changes in the Pre-SD SIC upon treatment, we performed 16S  
444 sequencing after 48 h of treatment with 2, 8, and  $32 \mu\text{g/mL}$  ciprofloxacin in each of the  
445 three consecutive passages (Fig. 4Ai,ii,iii). At  $2 \mu\text{g/mL}$ , diversity of the Pre-SD SIC  
446 decreased relative to the untreated SIC in the first passage (Fig. 4D). At  $32 \mu\text{g/mL}$ , the  
447 diversity of the Pre-SD SIC declined to levels lower than those of SICs derived from  
448 residual-treatment inocula of the same SD mouse in the absence of ciprofloxacin (Fig.  
449 2D, 4D), suggesting that the  $2\text{-}32 \mu\text{g/mL}$  range encompasses those experienced by the  
450 microbiota *in vivo*. For all doses, many families in the Pre-SD SIC decreased to



451 undetectable levels, including the abundant Enterobacteriaceae and Enterococcaceae  
452 (Fig. 4E), consistent with the drop in maximum OD relative to the untreated SIC (Fig.  
453 2G, 4B). Members of the Lachnospiraceae, Ruminococcaceae, and Bacteroidaceae  
454 persisted after three rounds in 2 and 8  $\mu\text{g}/\text{mL}$  ciprofloxacin (Fig. 4E). At 32  $\mu\text{g}/\text{mL}$ , the  
455 Ruminococcaceae were undetectable by the second passage and the Bacteroidaceae  
456 decreased to very low levels (Fig. 4E), likely explaining the large decrease in maximum  
457 OD relative to 16  $\mu\text{g}/\text{mL}$  (Fig. 4B).

458

459 Next, we examined changes at the ASV level to assess within-family dynamics. In the  
460 Pre-SD SIC, antibiotic pressure can select for strains that emerge from below the  
461 detection limit due to the decrease of other, more sensitive species: at 2  $\mu\text{g}/\text{mL}$  the  
462 Lachnospiraceae increased from 12 to 16 detectable ASVs while the Bacteroidaceae  
463 decreased from 12 to 4 detectable ASVs. At every concentration, the changes were  
464 highly reproducible between replicates (more than 89% and 69% of ASVs that became  
465 undetectable or detectable, respectively, did so in both replicates). To test whether the  
466 observed changes were explained by the sensitivities of each family to ciprofloxacin, we  
467 measured the MIC of the 15 strains isolated from a Pre-MD SIC (Fig. 3A, Table S1). The  
468 isolate MICs were highly correlated with the fractional change in abundance upon 2  
469  $\mu\text{g}/\text{mL}$  ciprofloxacin treatment of the Pre-SD SIC (Fig. 4F). These data show that the  
470 compositional changes observed in SICs can largely be predicted by individual

471 sensitivities in isolation.

472

473 ***SICs can predict in vivo compositional changes due to ciprofloxacin***

474 While a drug concentration can be measured in fecal samples, it is usually

475 undetermined along the gastrointestinal tract and potentially heterogeneous in space

476 and time. Other variables are currently impossible to measure and control, such as

477 environmental reservoirs that could play a role in bacterial migration and repopulation.

478 Our SICs provide the opportunity to study antibiotic perturbations in a precisely

479 controlled and high-throughput manner, to assess similarity to *in vivo* behavior, and to

480 interpret changes *in vivo* mechanistically.

481

482 Humanized mice treated with ciprofloxacin harbored high levels of Lachnospiraceae

483 and Ruminococcaceae at the peak of treatment (Fig. S1A), in agreement with the

484 selection of these families in SICs (Fig. 4E). Of the families for which we obtained MICs

485 (Table S1), the highest MIC was observed in the Lachnospiraceae, and this family

486 remained high or increased in relative abundance upon residual treatment *in vivo* (Fig.

487 5A). Most sensitive families (MIC <32 µg/mL) decreased in abundance (Fig. 5A, Fig.

488 S1M); the lone exception was the Bacteroidaceae, which increased in three of four mice

489 (Fig. 5A), consistent with our previous observation that a highly resistant *Bacteroides*

490 *vulgatus* strain (MIC >512 µg/mL) can be selected *in vivo* (Ng et al., 2019). Again, these

491 results suggest that the effective concentration *in vivo* is between 2 and 32  $\mu\text{g}/\text{mL}$ . These  
492 similarities suggest that ciprofloxacin sensitivities are generally similar *in vitro* and *in*  
493 *vivo*, and that individual sensitivities largely dictate the initial dynamics of SIC  
494 composition *in vivo*.

495

496 *In vivo*, the microbiota undergoes a complex recovery that likely involves differential  
497 susceptibilities, intrinsic recovery capacities, the emergence of resistant mutants, and  
498 metabolic interactions (Ng et al., 2019). To investigate the response of SICs in conditions  
499 resembling recovery from treatment *in vivo*, we diluted the Pre-SD SIC into plates  
500 without ciprofloxacin after one round in ciprofloxacin (Fig. 5Bi,iv,v). The Pre-SD SIC  
501 exhibited increases in maximum growth rate after one round of treatment at all doses  
502 (Fig. 5C); at low doses, growth rate rebounded to values similar to those before  
503 treatment, while at  $>8 \mu\text{g}/\text{mL}$  it only partially recovered (Fig. 5C). All the doses at which  
504 maximum growth rate increased back to similar levels to those before treatment  
505 showed recovery of the Enterococcaceae (Fig. S7A), in line with the correlation of the  
506 presence of this family and maximum growth rate (Fig. 2B) and the MIC of *Enterococcus*  
507 isolates (2-4  $\mu\text{g}/\text{mL}$ , Table S1). Removal of the drug slightly increased diversity in Pre-  
508 SD SICs (Fig. 5D), indicating that the recovery of certain species drives the partial  
509 recovery of growth rate. Thus, diversity recovery *in vitro* and *in vivo* (Fig. S1B) can be  
510 partially explained by re-emergence of ASVs that became undetectable during

511 treatment.

512

513 We next computed the extent of compositional disruption during treatment and the  
514 degree of recovery after treatment based on the Bray-Curtis dissimilarity index.

515 Ciprofloxacin dose determined the dissimilarity between the Pre-SD SIC before

516 treatment and after three passages in ciprofloxacin (Fig. 5E). The compositions of the

517 treated SICs were highly reproducible at the ASV level, especially at low concentrations

518 (Fig. S7B). After removing the drug from the highest-concentration conditions, the SICs

519 became more similar to, although still differed substantially from, the untreated state

520 (Fig. 5E). Interestingly, at lower concentrations the dissimilarity increased after removal

521 of the drug (Fig. 5E) due to the survival and expansion of taxa that were present at very

522 low abundance before ciprofloxacin treatment. This non-monotonic dose-response is

523 reminiscent of the better recovery of the microbiota in mice during high-dose compared

524 with low-dose osmotic diarrhea (Tropini et al., 2018). SICs hence adopt a new steady

525 state after ciprofloxacin exposure and recovery, as we previously observed *in vivo* (Ng

526 et al., 2019).

527

528 The small increase in SIC diversity after ciprofloxacin removal (Fig. 5D) was associated

529 with the recovery of Erysipelotrichaceae, Ruminococcaceae, and Enterococcaceae

530 members from below the limit of detection (Fig. 5F). The Erysipelotrichaceae family

531 recovered from one treatment at all concentrations (Fig. 5F), consistent with its recovery  
532 *in vivo* post-treatment (Fig. S1A). A second treatment after one passage without the  
533 drug (Fig. 5Bvi) again made the Erysipelotrichaceae undetectable (Fig. S7C), indicating  
534 that sensitivity to ciprofloxacin was the same before and after one treatment-recovery  
535 cycle. The other families did not recover from undetectable levels after removing the  
536 drug (Fig. 5F). Of the families that became undetectable, the only one to exhibit different  
537 recovery characteristics *in vitro* and *in vivo* (Fig. 5F,G,H, S7D) was the Bacteroidaceae,  
538 which were undetectable at 32  $\mu\text{g}/\text{mL}$  ciprofloxacin *in vitro* but persisted *in vivo*. Taken  
539 together, these results show that *in vitro* perturbations can be used as a proxy for many  
540 aspects of *in vivo* dynamics.

541

#### 542 ***Bacteroides* recovery in vitro is due to a combination of resistance and resilience**

543 The unexpected recovery of the Bacteroidaceae *in vivo* motivated us to probe the  
544 dynamics of these ASVs. *In vivo*, although most *Bacteroides* ASVs were undetectable at  
545 the peak and residual time points, most reappeared post-treatment (Fig. 5I, S7E). Only  
546 *B. vulgatus* in relative abundance to become dominant during residual treatment (Fig.  
547 5I, S7E); this strain was likely highly resistant to ciprofloxacin based on our assessment  
548 of *Bacteroides* isolates from the residual fecal sample (Ng et al., 2019). Consistent with  
549 this observation, *B. vulgatus* was the only Bacteroidaceae ASV that was present *in vitro*  
550 after 3 passages with 32  $\mu\text{g}/\text{mL}$  ciprofloxacin, reaching a stable abundance (Fig. 5J). *B.*

551 *caccae* and *B. uniformis* were present after 3 passages at 8 µg/mL, and *B. thetaiotaomicron*  
552 was present after 3 passages at 2 µg/mL (Fig. 5J); all three species recovered *in vivo* post-  
553 treatment (Fig. 5I). Other *Bacteroides* spp., such as *B. fragilis*, became undetectable after  
554 one passage at 2 µg/mL (Fig. 5J). These trends are consistent with the higher MICs of *B.*  
555 *uniformis* and *B. thetaiotaomicron* compared to *B. fragilis* (Table S1). Thus, sensitivities of  
556 isolates are predictive of *Bacteroides* resistance during continuous ciprofloxacin  
557 treatment in SICs.

558

559 Like *B. fragilis*, *B. intestinalis* was undetectable by the second passage even at the lowest  
560 ciprofloxacin concentration tested *in vitro* (Fig. 5J). Nonetheless, both species recovered  
561 *in vivo* in SD mice (Fig. 5I). Remarkably, these species also re-emerged *in vitro* when  
562 ciprofloxacin-treated SICs were diluted into medium without the drug (Fig. 5K). *B.*  
563 *fragilis* increased in relative abundance and became dominant after treatment with 2  
564 µg/mL (Fig. 5K), while *B. intestinalis* was detected only after 8 µg/mL (Fig. 5K),  
565 suggesting that competition with other species or taxa at the lower concentration drove  
566 *B. intestinalis* to undetectable levels. After treatment with 32 µg/mL, no *Bacteroides*  
567 species recovered (Fig. 5K). We refer to the ability of these strains to recover from  
568 undetectable levels during treatment as “resilience”. Interestingly, *B. vulgatus* was only  
569 detected when the SIC was continuously exposed (Fig. 5J) and not after ciprofloxacin  
570 was removed (Fig. 5K), suggesting that the recovery of other taxa can drive resistant

571 members to undetectable levels. Species that did not recover *in vivo*, such as *B. ovatus*,  
572 did not recover *in vitro* (Fig. 5I,K). These data demonstrate that fecal-derived SICs can  
573 recapitulate species-level dynamics observed *in vivo* and can distinguish between  
574 resistance and resilience. Our observations of species resilience within complex SICs  
575 also show that re-seeding from environmental reservoirs is not necessary for species to  
576 recover after antibiotic treatment.

577

### 578 ***Exposure to ciprofloxacin in vivo leads to functional differences in vitro***

579 The compositions of SICs derived during and after antibiotic treatment resembled the  
580 compositions of the inocula (Fig. 2A,C). Thus, we next asked whether the SICs retained  
581 functions observed *in vivo*: decreased resistance to colonization by the pathogen  
582 *Salmonella enterica* serovar Typhimurium (Barthel et al., 2003; Lawley et al., 2008) and  
583 increased resilience to a second round of treatment (Ng et al., 2019).

584

585 First, we asked whether exposure to ciprofloxacin led to compositional changes that  
586 reduce colonization resistance in the absence of the drug *in vitro*. We grew SICs derived  
587 from SD mice inocula gathered before, during the peak of, during residual, and after  
588 treatment *in vivo* (Pre-SD, Peak-SD, Res-SD, and Post-SD, respectively, Fig. 6A) in BHI.  
589 We challenged these SICs with *S. Typhimurium* for 48 h in BHI, diluted them, spotted  
590 them onto LB-streptomycin agar plates, and incubated them in aerobic conditions to

591 select for *S. Typhimurium*. Pre-SD SICs had >10-fold less *S. Typhimurium* than  
592 communities derived from feces of ciprofloxacin-treated mice (Fig. 6B, S8A). Single-cell  
593 quantification of fluorescently tagged *S. Typhimurium* revealed an even larger  
594 difference in colonization efficiency between the Pre-SD and Res-SD SICs (Fig. 6C, S8B).  
595 Thus, changes in composition driven by antibiotic treatment *in vivo* lead to differences  
596 in SICs that mimic the resilience of the microbiota to pathogen invasion *in vivo*.

597

598 Second, we asked whether the pre-exposed, low-diversity Res-SD SIC showed higher  
599 resilience to ciprofloxacin *in vitro* than the Pre-SD SIC (Fig. 6D). We grew the SICs in  
600 BHI with ciprofloxacin continuously (Fig. 6Di,ii,ii) or transiently (Fig. 6Di,iv,v) as  
601 above. The Res-SD SIC was less sensitive than the Pre-SD SIC in terms of growth rate  
602 (Fig. 4B, 6E), and the final OD was largely unaffected (Fig. 6E).

603

604 We next asked whether the robustness of Res-SD SIC growth behaviors (Fig. 6E) during  
605 ciprofloxacin treatment could be explained by particular compositional differences from  
606 the Pre-SD SIC. The Res-SD SIC displayed responses distinct from those of the Pre-SD  
607 SIC, maintaining diversity even at the highest ciprofloxacin concentrations (Fig. 4C, 6F).

608 At all concentrations, Bacteroidaceae and Lachnospiraceae dominated even after three  
609 passages (Fig. 6G), in contrast to the elimination of most Bacteroidaceae in the Pre-SD  
610 SIC (Fig. 4E). The most abundant family that was subsequently lost from Res-SD SIC



611 was the Enterococcaceae (Fig. 6G); the Ruminococcaceae and Verrucomicrobiaceae were  
612 lost at 32 and 2 µg/mL ciprofloxacin, respectively (Fig. 6G). These losses were  
613 counterbalanced by emergent ASVs within the resistant families. As with the Pre-SD  
614 inocula, composition was quantitatively similar at the ASV level between the two  
615 replicates at low ciprofloxacin concentrations (Fig. S7G). At 32 µg/mL, the two  
616 replicates were more similar to each other than to the Pre-SD SIC after treatment (Fig.  
617 S7D), suggesting that pre-exposure to the drug in mice decreases the stochastic nature  
618 of species elimination upon subsequent exposure *in vitro*.

619

620 The compositions of the Res-SD SIC before treatment and after two recovery passages  
621 were highly similar at low doses (Fig. 6H). For all doses, the dissimilarity index of the  
622 post-recovery Res-SD SIC reverted toward its original state (Fig. 6I); by contrast, at 2  
623 µg/mL ciprofloxacin, the Pre-SD SIC was further remodeled during recovery (Fig. 5E).  
624 These data imply that the members of the Res-SD SIC are more resistant to the drug  
625 than members of the Pre-SD SIC, in line with their pre-selection *in vivo*.

626

627 Both *in vitro* for the Pre-SD SIC and *in vivo*, we observed selection of *B. vulgatus* upon  
628 treatment with ciprofloxacin (Fig. 5I,J). However, in the absence of ciprofloxacin, *B.*  
629 *fragilis* dominated the Bacteroidaceae of the Res-SD SIC (Fig. 6J), consistent with this  
630 species' ability to recover and dominate the Pre-SD SIC after ciprofloxacin removal (Fig.

631 5K), while *B. vulgatus* and *B. caccae* were at low relative abundances (Fig. 6J). *B. fragilis*  
632 became undetectable during Res-SD treatment regardless of concentration, as did *B.*  
633 *caccae* at 32  $\mu\text{g}/\text{mL}$  (Fig. 6J). *B. vulgatus* accounted for the totality of the Bacteroidaceae at  
634 32  $\mu\text{g}/\text{mL}$  (~20% of the SIC; Fig. 6G,J). At 2  $\mu\text{g}/\text{mL}$ , the *B. fragilis* ASV re-emerged after  
635 two recovery passages in one replicate at the expense of *B. vulgatus* (Fig. 6K), similar to  
636 the replacement of the resistant *B. vulgatus in vivo* by other *Bacteroides* (Fig. 5I). Thus,  
637 SICs derived from residual inocula are generally more resilient to ciprofloxacin and  
638 exhibited *Bacteroides* dynamics similar to *in vivo* treatment. These data suggest that the  
639 initial treatment culls the community down to a resistant core, leading to a community  
640 that is stable under further treatment.

641

#### 642 *Diverse, stable SICs can be generated directly from human fecal samples*

643 Our experiments consistently showed that passaging of fecal samples from humanized  
644 mice can lead to stable SICs preserving many of the taxa from the original sample. What  
645 about feces sampled directly from humans? Three human stools from anonymous  
646 donors were more diverse than the humanized mice fecal samples (Fig. 2D,S1B), with  
647 115-219 ASVs. We passaged the samples in BHI and observed trends of rapid  
648 convergence to a stable steady state and high family-level diversity similar to SICs  
649 derived from humanized mice (Fig. 7A); SIC composition stabilized in  $3.1 \pm 0.3$  passages,  
650 and the mean richness after the 8<sup>th</sup> passage was  $46.4 \pm 2.4$  ASVs ( $n=3$ ).

651

652 Steady-state compositions of the passaged SICs were reproducible across technical  
653 replicates (Fig. S9A), but across donors, the SICs differed at the family level, with >50%  
654 of families being unique to one donor (Fig. 7A, S9B). Of the 103 unique ASVs across all  
655 human stool-derived SICs, only 9 were shared among SICs derived from all three  
656 donors (6 *Bacteroides* spp., 1 Lachnospiraceae, 1 Enterobacteriaceae, 1  
657 Ruminococcaceae). Families that were shared among the three human stool-derived  
658 SICs were highly overlapping with those of the core microbiota from our other  
659 humanized mouse-derived passaged SICs (Fig. 7B, S9C). Moreover the relative  
660 abundances of these ASVs were similar in all human stool-derived SICs (Fig. S9B).

661

662 To compare to humanized mouse SICs, we performed a PCoA on humanized mouse  
663 and human stool SICs together, considering the presence or absence of ASVs  
664 (unweighted Unifrac distances, Fig. 7C). SICs from two stool samples had phylogenetic  
665 compositions (weighted Unifrac distances) similar to those of their inocula (the  
666 corresponding human stool sample), while the third sample was more different from  
667 the final SICs (Fig. 7D) due largely to the emergence of the Eubacteriaceae and  
668 Enterococcaceae from undetectable to  $0.29 \pm 0.13\%$  and  $4.9 \pm 1.1\%$ , respectively.  
669 Nonetheless, the final SICs derived from human stool after 7 passages were as (or more)  
670 similar to their inocula than the humanized mouse-derived SICs were to their inocula

671 (the corresponding mouse fecal sample) using phylogenetic distance metrics (Fig.  
672 7C,D). Taken together, these data demonstrate that *in vitro* batch culturing of human  
673 stool samples is a generally applicable tool to build complex, stable, and reproducible  
674 SICs.

675 **Discussion**

676 Here, we have shown that *in vitro* passaging of fecal samples is a powerful tool for  
677 generating stable, host-relevant SICs in a deterministic and reproducible manner (Fig.  
678 1G,H,S2A). Remarkably, this reproducibility even extends to a highly perturbative  
679 antibiotic treatment that causes large-scale compositional changes (Fig. S7B,G). SICs  
680 rapidly converge (Fig. 1D,S1L) and can be frozen (Fig. 1J) and cultured in larger  
681 volumes (Fig. 1I) without disrupting steady-state composition, demonstrating their  
682 utility for large-scale manufacturing and experimentation. Particular media may be  
683 useful for enhancing the abundance of certain desired families, while antibiotics and  
684 bacteriophages may be useful to remove undesirable taxa. Importantly, our observation  
685 that different inocula yield different SICs (Fig. 2, 7) showcases the potential of SICs for  
686 personalized therapeutics.

687

688 While our approach yields SICs that are more complex than ones typically studied with  
689 bottom-up approaches, the scaling of richness with growth yield (Fig. 2E) suggests that  
690 niche occupancy in BHI is saturated at ~50 species, leading to competitive exclusion  
691 (Del Monte-Luna et al., 2004). It will be intriguing to investigate whether it is possible to  
692 achieve higher richness in other media, or by supplementing BHI with vitamins,  
693 cofactors, or specific nutrients such as mucin to promote the growth of fastidious  
694 organisms (Tramontano et al., 2018), like the Verrucomicrobia. Cross-feeding may

695 increase richness and reshape community composition via niche generation (Goldford  
696 et al., 2018). Conversely, media composed of monomeric and dimeric carbon sources  
697 that are absorbed in the small intestine select for a few dominant species (Fig. S1K). A  
698 better understanding of the contributions of interspecies interactions and nutrient  
699 availability to community diversity and yield will be instrumental to engineering  
700 culturing systems to achieve the bacterial density and diversity observed in the gut. Our  
701 SICs represent a major step toward this goal.

702

703 Strikingly, while YCFA supports the growth of a wide range of gut commensals in pure  
704 cultures, in SICs the Enterococcaceae tend to take over (Fig. S1J, S3A), indicating that  
705 media that support the growth of many isolates do not necessarily support diverse  
706 SICs. Further, the ability of species to grow in isolation is generally not a good predictor  
707 of their relative abundance within an SIC (Fig. 3L). While the maximal growth rate of  
708 SICs scales with the fraction of fast growers (Fig. 2F), fast growers are quickly limited  
709 (Fig. 3M). Thus, fast growers probably dictate SIC growth rate, but final composition is  
710 determined by many other factors, which explains why BHI SICs are far more diverse  
711 than a scenario in which the rapid growers take over. Measurements beyond SIC  
712 composition—such as consumption and production of metabolites, growth and death  
713 rates of species, and global environmental properties such as pH and osmolarity—will  
714 enable a mechanistic understanding of community niche dynamics. Since SIC

715 composition can be approximately mimicked with reference strains (Fig. I,K),  
716 incorporating genetically modifiable organisms and existing mutant libraries in our  
717 SICs could open additional applications.

718

719 A remarkable aspect of our SICs is their ability to recapitulate *in vivo* behaviors.  
720 Community composition was generally maintained through passaging in BHI (Fig. 1,7)  
721 and the microbial metaproteomic signature was similar between feces and SICs (Fig.  
722 S1E), suggesting that many interspecies interactions are conserved in this medium.  
723 Moreover, SICs derived from mice during and after antibiotic treatment were more  
724 susceptible to invasion by *S. Typhimurium* than SICs derived before treatment (Fig. 6A-  
725 C). While previous studies reported that ciprofloxacin treatment can increase the  
726 colonization susceptibility of chemostat-grown microbial communities (Carman et al.,  
727 2004), our experiments were conducted in the absence of ciprofloxacin at the time of  
728 challenge. Thus, the compositional changes elicited by antibiotics *in vivo* are maintained  
729 *in vitro*, leading to different functional outcomes.

730

731 Importantly, our study also allowed a quantitative comparison between the antibiotic  
732 response of the gut microbiota *in vivo* and *in vitro* (Fig. 5), which revealed remarkable  
733 similarities in taxon-specific changes in diversity (Fig. 5H). Many aspects of the  
734 recovery dynamics that are confounded by multiple factors *in vivo* were clarified by our

735 *in vitro* studies. The lack of substantial recovery in richness *in vitro* after ciprofloxacin  
736 treatment (Fig. 5D) suggests that the ~4-fold increase *in vivo* post-treatment relative to  
737 residual samples (Fig. S1B) comes from environmental reseeded or increased densities  
738 *in vivo*. Notably, SICs derived from feces at the peak or during residual treatment were  
739 more similar to their inocula than to feces post-treatment (Fig. 2A), indicating that  
740 removal of the drug in inoculating media *in vitro* is not enough to recover taxa that  
741 went undetectable *in vivo*. Highlighting the physiological relevance of such reservoirs,  
742 our *in vivo* studies indicate that singly housed mice experience a prolonged decrease in  
743 viable load, *Bacteroides* abundance, and diversity compared with co-housed mice during  
744 antibiotic treatment, with highly heterogeneous recovery dynamics across mice (Ng et  
745 al., 2019). Disruption of community composition and the set of species that become  
746 undetectable are mostly deterministic (Fig. S9C,H). Our findings show that the recovery  
747 of some species such as *B. fragilis* from undetectable levels across multiple passages  
748 does not require environmental reservoirs (e.g. via coprophagy in mice) or larger  
749 population sizes *in vivo*, indicating that resilience is built-in to some species, and  
750 pointing to SICs enabling the elucidation of aspects of community ecology that can be  
751 uncoupled from host dependence. Future work with fecal-derived SICs, including  
752 comparisons of our methodology with other fecal-derived and bottom-up reconstitution  
753 approaches (Macfarlane et al., 1998; Minekus et al., 1999; Van de Wiele et al., 2015),



754 should elucidate the interplay among antibiotic sensitivity and tolerance, duration, and  
755 strength of antibiotic exposure, and migration between hosts and the environment.

756

757 In general, top-down and bottom-up SICs serve as powerful, complementary resources  
758 for the microbiota field. Bottom-up SICs can be used to measure interspecies  
759 interactions using drop-out experiments (Gutierrez and Garrido, 2019), while top-down  
760 SICs provide a more complex template for evaluating the effects of perturbations and  
761 comparing to *in vivo* results, including the potential for blooming of species from below  
762 the limit of detection pre-treatment. The overrepresentation of fast-growing species in  
763 SICs (Fig. 1) and their receding in SIC-colonized mice (Fig. S1C,D) shed light on the  
764 bacterial taxa whose growth is controlled by the host. Further, we predicted the effects  
765 of ciprofloxacin (Fig. 4G) at the ASV level through isolate-sensitivity measurements and  
766 perturbations to pre-treatment SICs. The emergence of resistant strains, and their out-  
767 competition by close relatives, can also be predicted (Fig. 6). The observed correlation  
768 between changes upon ciprofloxacin treatment and strain sensitivities (Fig. 4F) suggests  
769 that interspecies interactions are not a strong modifier of antibiotic responses in these  
770 SICs. Nonetheless, interspecies interactions can change antibiotic sensitivity in  
771 auxotrophic food-webs (Adamowicz et al., 2018) and induce tolerance (Aranda-Díaz et  
772 al., 2019). Notably, we can only measure isolate sensitivities in the culturable portion of  
773 the SICs (Fig. 3B), and metabolic dependencies of the strains we did not isolate could

774 affect their survival. Further work will be needed to investigate the role of tolerance in  
775 the ability of specific taxa to recover after treatment (Fig. 5F,K). These findings suggest  
776 that first dissecting *in vitro* how a gut community is remodeled by a perturbation can  
777 serve as a powerful pre-screening tool before expensive mouse experiments.

778

779 Many other fascinating questions should be tackled in the future using our *in vitro*  
780 approach, which can be scaled to thousands of SICs simultaneously. Since a fecal  
781 sample from a mammalian host likely represents an average over the spatial  
782 localization and physiologies determined by the history and environmental contexts  
783 within the gut, a similar culturomics approach should be applied to samples from other  
784 locations in the gastrointestinal tract. Our observation that BHI-passaged SICs can shift  
785 the host proteome of germ-free mice toward that of humanized mice (Fig. S1D) suggests  
786 that SICs can also be safely re-introduced to their original hosts. Fecal microbiota  
787 transplantation is a promising therapy for diseases like *Clostridium difficile* infection  
788 (Drekonja et al., 2015) and aids in recovery after chemotherapy (Le Bastard et al., 2018),  
789 diarrhea (Tropini et al., 2018), and antibiotic treatments (Ng et al., 2019). However, the  
790 lack of standardization and danger due to potential collateral infections are major  
791 barriers for the wide therapeutic use of fecal microbiota transplantation (Cammarota et  
792 al., 2017). SICs may lower the risk of infection and improve manufacturing efficiency  
793 (Khoruts and Weingarden, 2014), thus overcoming these barriers to therapy. More

794 generally, SICs should bridge mechanistic studies of microbial ecology and human-  
795 relevant *in vivo* systems to accelerate the pace of discovery in the microbiota field.

796 **Author Contributions**

797 A.A.-D, K.M.N., J.L.S., and K.C.H designed the research; A.A.-D., K.M.N., T.T., S.D.,  
798 F.B.Y., I.R.R., T.C., S.H, K.V., C.G.G., and T.N. performed the research; A.A.-D., K.M.N.,  
799 D.D., and C.G.G. analyzed the data; and A.A.-D, J.L.S., and K.C.H wrote the paper and  
800 all authors reviewed it before submission.

801

802 **Acknowledgments**

803 The authors thank Rebecca Culver, Carolina Tropini, Kali Pruss, Alice Cheng,  
804 Manohary Rajendram, Surya Tripathi, and Myles Bartholomew for technical assistance;  
805 and Rita Oliveira, Lisa Willis, Handuo Shi, and Po-Yi Ho for valuable comments on the  
806 manuscript. Some reference strains used in this study were kindly provided by Michael  
807 Fischbach and Denise Monack. A.A.-D. is a Howard Hughes Medical Institute  
808 International Student Research fellow, a Stanford Bio-X Bowes fellow, and a Siebel  
809 Scholar. The authors acknowledge funding from the Allen Discovery Center at Stanford  
810 on Systems Modeling of Infection (to K.M.N. and K.C.H.). J.L.S. and K.C.H. are Chan  
811 Zuckerberg Investigators.

812 **Methods**

813

814 *Mouse sampling*

815 All mouse experiments were conducted in accordance with the Administrative Panel on

816 Laboratory Animal Care, Stanford University's IACUC. Germ-free, female, Swiss-

817 Webster mice were gavaged with a human fecal sample obtained from a healthy

818 anonymous donor as previously described (Kashyap et al., 2013). The microbiota was

819 allowed to equilibrate for 6-8 weeks before perturbation experiments commenced.

820 Humanized mice were orally gavaged with antibiotics (Sigma Aldrich) dissolved in 200

821  $\mu$ L water for 5 days. For experiments involving a dietary switch, mice were first fed a

822 standard diet (Purina LabDiet 5010) rich in MACs, and then a defined low-MAC diet

823 (Harlan TD.86489) in which the sole carbohydrates are sucrose (31% w/w), cornstarch

824 (31% w/w), and cellulose (5% w/w). Mice were euthanized with CO<sub>2</sub> and death was

825 confirmed via cervical dislocation.

826

827 Fecal pellets were sampled on ice and taken into an anaerobic chamber within 30 min.

828 Human stool samples were collected from 3 healthy donors by scooping a small sample

829 from a receptacle into a conical tube on ice. The samples were transferred to an

830 anaerobic chamber within 5 min of sampling.

831

832 *SIC passaging, storage, and revival*

833 Approximately 100 mg of stool samples from humanized mice or human donors were  
834 resuspended into 200  $\mu$ L phosphate-buffered saline (PBS) in 1.5 mL microcentrifuge  
835 tubes. Samples were incubated in PBS for 10-15 min at room temperature to encourage  
836 large pieces of fecal matter to disintegrate. Samples were vortexed for 5 min and  
837 allowed to sit for 1 min to let food particles settle. One microliter of this resuspension  
838 was inoculated into 200  $\mu$ L medium in 96-well polystyrene microplates (Greiner Bio-  
839 One). Each resuspension was inoculated into four media (Table S2) in triplicate. The  
840 plate was covered with optical film, with a small (~0.5 mm) hole poked above each well,  
841 outside of the plate reader's light path, to allow gas exchange.

842

843 Incubation and optical density (OD) measurements were performed with an Epoch 2  
844 plate reader (BioTek) in an anaerobic chamber at 37 °C with continuous shaking and  
845 OD<sub>600</sub> measured at 7.5-min intervals. Plates were incubated in the plate reader for 48 h  
846 and then 1  $\mu$ L of this saturated culture was transferred into 200  $\mu$ L of fresh medium in a  
847 new plate. We refer to a 48-h cycle from inoculation to saturation as one passage.

848 Samples used in the passaging experiments in Figs. 1 and 2 were taken in consecutive  
849 days, hence the plate was removed from the plate reader every 24 h, to inoculate and/or  
850 passage corresponding SICs. On a given day, if the communities were not passaged,

851 then the whole volume was transferred into a new plate.

852

853 After passaging, 50  $\mu$ L of the cultures were mixed with 50  $\mu$ L sterile 50% glycerol (v/v  
854 in water) in crimp vials, sealed, and stored at -80 °C for long-term storage. The  
855 remaining volume was stored in the 96-well plate at -80 °C with an aluminum seal until  
856 DNA was extracted. BHI SICs were revived for experimentation by inoculation of  
857 frozen glycerol stocks directly into 3 mL BHI. Revived communities were incubated at  
858 37 °C for 48 h and passaged twice before experimentation by diluting 1:200 into fresh  
859 medium every 48 h.

860

### 861 *SIC colonization*

862 Mice were humanized with a human fecal sample obtained from the same healthy  
863 anonymous donor as was used for the ciprofloxacin-treatment experiment (Fig. 1A).  
864 Four weeks after humanization, fecal pellets were collected from 11 mice housed across  
865 3 cages. A mixture of the 11 fecal pellets was used to inoculate 3 mL BHI to derive an  
866 SIC as described above. The SIC was passaged every 48 h with a 1:200 dilution into  
867 fresh medium. After 5 passages, a frozen stock was made by mixing equal volumes of a  
868 saturated culture and 50% glycerol (v/v in water). The SIC was revived by inoculating  
869 the frozen stock into 3 mL BHI and passaging twice before using 200  $\mu$ L of the saturated  
870 culture to gavage germ-free, female, Swiss-Webster mice. Fecal pellets were

871 sampled from the germ-free mice on the day that they were gavaged, on day 24 after  
872 colonization for proteome analysis, and on day 28 for 16S sequencing.

873

#### 874 *Strains and growth media*

875 Growth media are listed in Table S2. These media were chosen because of their ability  
876 to grow diverse microbes: the nutrient-rich Brain Heart Infusion (BHI) is widely used to  
877 culture fastidious microorganisms; Tryptone-Yeast extract-Glucose (TYG), which is  
878 often used to culture members of the *Bacteroides* genus that includes many prevalent  
879 human commensals; Gifu Anaerobic Medium (GAM; a mixture of animal, plant, and  
880 yeast digests and extracts supplemented with glucose and starch), which cultures  
881 individual species with relative yields similar to their abundances in human  
882 microbiotas (Rettedal et al., 2014); and Yeast extract, Casitone, and Fatty Acids (YCFA),  
883 which has been used to culture a wide range of human gut commensals (Browne et al.,  
884 2016). Isolated and reference strains are listed in Tables S1 and S3, respectively. All  
885 media and materials were made anaerobic by incubating in a custom anerobic chamber  
886 (Coy Labs) for 48 h before use.

887

#### 888 *Growth analyses*

889 Maximal growth rate was calculated as the maximal slope of  $\ln(\text{OD})$  with respect to  
890 time (calculated from a linear regression of a sliding window of 11 timepoints). The



891 duration of lag phase was defined as the time at which a strain first reached its half-  
892 maximum growth rate.

893

#### 894 *16S rRNA sequencing*

895 DNA was extracted from whole fecal pellets or 50  $\mu$ L of culture with a DNeasy  
896 PowerSoil HTP 96 kit (Qiagen 12955-4). 16S rRNA amplicons were generated using  
897 Earth Microbiome Project-recommended 515F/806R primer pairs using the 5PRIME  
898 HotMasterMix (Quantabio 2200410) with the following program in a thermocycler: 94  
899  $^{\circ}$ C for 3 min, 35 cycles of 94  $^{\circ}$ C for 45 s, 50  $^{\circ}$ C for 60 s, and 72  $^{\circ}$ C for 90 s, followed by 72  
900  $^{\circ}$ C for 10 min. PCR products were cleaned, quantified, and pooled using the UltraClean  
901 96 PCR Cleanup kit (Qiagen 12596-4) and Quant-iT dsDNA High Sensitivity Assay kit  
902 (Invitrogen Q33120). Samples were sequenced with 250- or 300-bp reads on a MiSeq  
903 (Illumina).

904

905 Samples were de-multiplexed with Qiime v. 1.9.1 (Caporaso et al., 2010) using the  
906 commands “split\_libraries\_fastq.py --rev\_comp\_mapping\_barcodes --  
907 rev\_comp\_barcode --store\_demultiplexed\_fastq --max\_bad\_run\_length 999 --  
908 min\_per\_read\_length\_fraction .01 --sequence\_max\_n 999 --phred\_quality\_threshold 0”  
909 and “split\_sequence\_file\_on\_sample\_ids.py”. Subsequent processing was performed  
910 using DADA2 as previously described (Callahan et al., 2016). truncLenF and truncLenR

911 parameters were set to 240 and 180, respectively. Resulting ASV sequences were  
912 assigned taxonomy with Qiime, using the commands “assign\_taxonomy.py”,  
913 “align\_seqs.py”, and “make\_philogeny.py”. Custom MATLAB R2018a (MathWorks)  
914 scripts were used for further analysis.

915

916 ASVs were classified as contaminants and removed from further analysis if they  
917 appeared with significantly higher relative abundances ( $p < 0.001$ , t-test) in control  
918 samples (water added to DNA extraction step).

919

920 Alpha diversity (richness) was measured by rarefying all samples to 5000 reads and  
921 calculating the number of taxa with relative abundance  $> 0$ . Shannon diversity was  
922 calculated using  $S = \sum_{i=1}^N -p_i \ln p_i$ , where  $p$  is the relative abundance of the  $i$ th taxon  
923 and  $N$  is the total number of taxa with  $p > 0$ . Evenness was calculated using the Pielou  
924 index by normalizing Shannon diversity by the maximum Shannon index for the

925 number of taxa:  $J = S / \ln N$ .

926

927 Weighted and unweighted Unifrac distances between samples for beta diversity were  
928 calculated using custom MATLAB code. Unifrac was calculated as described in  
929 (Lozupone and Knight, 2005). Weighted Unifrac was calculated as described in

930 (Lozupone et al., 2007): for samples  $A$  and  $B$ ,  $u_w = \sum_i^n b_i \times |A_i - B_i|$ , where  $n$  is the total

931 number of branches in the tree,  $b_i$  is the length of branch  $i$ , and  $A_i$  and  $B_i$  are the relative  
932 abundances of the taxa that descend from branch  $i$  in samples  $A$  and  $B$ , respectively. No  
933 further normalization was performed. Only taxa present at >0.01% in more than two  
934 samples were used to calculate distances. Principal coordinate analyses were performed  
935 on unweighted Unifrac distances between samples with >5000 reads.

936

### 937 *Isolation of strains*

938 SICs were resuspended in PBS and plated onto BHI, BHI-S, or GAM plates. Plates were  
939 incubated at 37 °C in an anaerobic chamber. After 2 days, colonies were grown in the  
940 medium corresponding to the plate from which they were isolated for 2 days, and  
941 glycerol stocked. Strains were identified via high-throughput MALDI-TOF mass  
942 spectrometry of whole colonies, and subsequent matching of spectra to a reference  
943 library with a MALDI Biotyper System (Bruker), following manufacturer's instructions  
944 and including formic acid lysis. For the SIC that we attempted to reconstitute, 15  
945 distinct strains were obtained and their taxonomy was checked by Sanger sequencing.  
946 Genomic DNA was extracted from pure cultures using a DNeasy UltraClean 96  
947 Microbial Kit (Qiagen 10196-4) or DNeasy Blood and Tissue Kit (Qiagen 69504) kit. The  
948 16S gene was amplified using primers 5' AGAGTTTGATCCTGGCTCAG and  
949 5' GACGGGCGGTGWGTRCA, and the amplicon was Sanger sequenced. Taxonomic

950 assignment was performed by alignment using BLAST against the 16S ribosomal RNA  
951 sequences (Bacterial and Archaea) database.

952

### 953 *Community reconstitution*

954 For community reconstitution, frozen stocks of isolated (Table S1) or reference (Table  
955 S3) strains were streaked onto BHI 5% sheep blood agar plates and incubated for 48 h at  
956 37 °C in anaerobic conditions. A single colony of each strain was inoculated into 3 mL  
957 BHI in isolation, and incubated for 48 h at 37 °C. OD was measured for each strain and  
958 all were diluted to a final OD of  $1 \times 10^{-4}$  before mixing in 200  $\mu$ L BHI in a 96-well plate.  
959 Mixed cultures were grown for 48 h in a plate reader to measure growth. After 48 h the  
960 cultures were diluted 1:200 into fresh BHI.

961

### 962 *Antibiotic sensitivity estimation*

963 Frozen stocks of isolated strains (Table S1) were streaked onto BHI 5% sheep blood agar  
964 plates and incubated for 48 h at 37 °C in anaerobic conditions. A single colony of each  
965 strain was inoculated into a 3 mL monoculture in BHI, and incubated for 48 h at 37 °C.  
966 Cultures were then diluted 1:200 into fresh BHI containing 0.5-32  $\mu$ g/mL ciprofloxacin.  
967 The minimum inhibitory concentration (MIC) for each strain was calculated as the  
968 minimum dose necessary to completely inhibit growth as measured by OD after 48 h of  
969 incubation.

970

971 ***In vitro antibiotic treatment***

972 SICs were revived in 3 mL BHI and passaged twice before experimentation by diluting  
973 15  $\mu$ L into 3 mL fresh medium every 48 h. One microliter of the SICs was then diluted  
974 into 200  $\mu$ L fresh BHI containing 0.5-32  $\mu$ g/mL ciprofloxacin. Growth was measured in  
975 a plate reader as described above, and 48 h-old cultures were stored at -80 °C until DNA  
976 was extracted.

977

978 ***In vitro S. Typhimurium challenge***

979 SICs were revived in 200  $\mu$ L BHI in microplates and passaged twice by diluting 1  $\mu$ L  
980 into 200  $\mu$ L fresh medium every 48 h. A frozen stock of *S. Typhimurium* strain SL1344  
981 was grown anaerobically at 37 °C for 24 h in BHI. One microliter of the SICs and 1  $\mu$ L of  
982 *S. Typhimurium* adjusted to OD<sub>600</sub>=0.1 was diluted into 200  $\mu$ L fresh BHI. Saturated co-  
983 cultures were serially diluted into sterile PBS after 48 h of incubation at 37 °C. Three  
984 microliters of a 1:10<sup>4</sup> dilution were spotted onto LB agar with 50  $\mu$ g/mL streptomycin to  
985 select for *S. Typhimurium*. Pictures of colonies (Fig. 6B, S8A) were taken after 48 h of  
986 incubation at 37 °C in aerobic conditions.

987

988 For single-cell quantification of *S. Typhimurium* levels, we followed the protocol  
989 described above to grow SICs and an *S. typhimurium* 14028s strain expressing

990 cytoplasmic mCherry (Table S3) prior to co-culturing. SICs and *S. Typhimurium* were  
991 mixed at various ratios and incubated anaerobically for 48 h at 37 °C. Saturated cultures  
992 were removed from the anaerobic chamber and spotted onto PBS agar plates to perform  
993 high-throughput phase and fluorescence microscopy (Shi et al., 2017). Percentages of *S.*  
994 *Typhimurium* (Fig. 6C, S8B) were estimated by calculating the proportion of pixels  
995 within cell contours segmented from phase images whose fluorescence was above a  
996 threshold that clearly separated mCherry-positive and mCherry-negative cells using  
997 custom Matlab code.

998

#### 999 *Isolation of stool proteins and peptides*

1000 Isolation of stool proteins broadly followed the protocol in (Gonzalez et al., 2020).  
1001 Briefly, ~50 mg mouse pellets or pelleted cells from 1 mL saturated cultures were  
1002 aliquoted into a 96-well plate along with ~600 mg of 0.1-mm ceramic beads (Omni  
1003 International, #27-6006). To each well, 750 µL lysis buffer (6 M urea, 5% sodium dodecyl  
1004 sulfate, and 50 mM Tris, pH 8.1) was added and plates were sealed with sealing mats  
1005 (Omni International, #27-530). Sealed plates were subjected to 10 min of bead beating at  
1006 20 Hz using a Qiagen Tissuelyser II. After bead beating, each plate was centrifuged at  
1007 3000 rcf at 4 °C for 10 min. Five hundred microliters of the resulting supernatant were  
1008 transferred to a new 2-mL 96-well plate (Waters, 186002482), sealed with a sealing mat,  
1009 spun again at 3000 rcf at 4 °C for 10 min, then transferred to a fresh 2-mL plate. Samples

1010 were reduced with 10  $\mu$ L of 500 mM dithiothreitol (Sigma-Aldrich) for 30 min at 47 °C  
1011 and alkylated with 30  $\mu$ L of 500 mM iodoacetamide (Sigma-Aldrich) for 1 h at room  
1012 temperature in the dark. Fifty microliters of the reduced and alkylated supernatant  
1013 were transferred to a new 2-mL 96-well plate for further processing, while the  
1014 remaining material was stored at -80 °C.

1015

1016 Supernatant-resident stool proteins were washed, digested, and eluted as described in  
1017 the Protifi S-trap protocol ([http://www.protifi.com/wp-content/uploads/2018/08/S-Trap-](http://www.protifi.com/wp-content/uploads/2018/08/S-Trap-96-well-plate-long-1.4.pdf)  
1018 [96-well-plate-long-1.4.pdf](http://www.protifi.com/wp-content/uploads/2018/08/S-Trap-96-well-plate-long-1.4.pdf)). Briefly, the 50  $\mu$ L supernatant was acidified with 5  $\mu$ L of  
1019 12% phosphoric acid to which 300  $\mu$ L S-trap binding buffer was added. Each resulting  
1020 mixture was loaded into a single well. Positive pressure was used to load the proteins  
1021 into each well with a Positive Pressure-96 Processor (Waters) with pressure set at 6-9 psi  
1022 on the “Low-Flow” setting. Loaded proteins were washed with 300  $\mu$ L Binding Buffer  
1023 (90% methanol and 10% triethylammonium bicarbonate buffer (TEAB, Sigma-Aldrich,  
1024 #T7408), adjusted to pH 7.1 using phosphoric acid) five times. After washing, 125  $\mu$ L  
1025 digestion buffer (100 mM TEAB and 5  $\mu$ g trypsin) were added and proteins were  
1026 digested for 3 h at 47 °C. Peptides were eluted with 100  $\mu$ L TEAB, followed by 100  $\mu$ L of  
1027 0.2% formic acid, followed by 100  $\mu$ L of 50% acetonitrile, 0.2% formic acid. These  
1028 peptides were captured in a 1-mL 96-well plate (Thermo Scientific, #AB-1127) and the  
1029 volume was dried down in a Centrivap speedvac (Model 7810016). Plated samples were

1030 desalted using RP-S cartridges on an Agilent Bravo AssayMAP using the built-in  
1031 desalting protocol, eluted with 50% acetonitrile, and dried down. Plated peptide  
1032 concentrations were normalized using a Nanodrop ND-1000.

1033

### 1034 *Mass spectrometry*

1035 Peptide samples were diluted to 0.5  $\mu\text{g}/\mu\text{L}$ . Subsequently, 1  $\mu\text{L}$  was loaded onto an in-  
1036 house, laser-pulled 100- $\mu\text{m}$  inner diameter nanospray column packed to ~220 mm with  
1037 3- $\mu\text{m}$  2A C18 beads (Reprosil). Peptides were separated by reversed-phase  
1038 chromatography on a Dionex Ultimate 3000 HPLC. Buffer A of the mobile phase  
1039 contained 0.1% formic acid in HPLC-grade water, and buffer B contained 0.1% formic  
1040 acid in acetonitrile. An initial 2-min isocratic gradient flowing 3% B was followed by a  
1041 linear increase to 25% B for 115 min, then increased to 45% B over 15 min, and a final  
1042 increase to 95% B over 15 min, whereupon B was held for 6 min and returned back to  
1043 baseline in 2 min and held for 10 min, for a total of 183 min. The HPLC flow rate was  
1044 0.400  $\mu\text{L}/\text{min}$ . Samples were run on a Thermo Fusion Lumos mass spectrometer that  
1045 collected mass spectrometry data in positive-ion mode within the 400-1500  $m/z$  range  
1046 with an initial Orbitrap scan resolution of 120,000, followed by high-energy collision-  
1047 induced dissociation and analysis in the orbitrap using “Top Speed” dynamic  
1048 identification with dynamic exclusion enabled (repeat count of 1, exclusion duration of



1049 90 s). The automatic gain control was set to 4e5 for FT full mass spectrometry and to 1e4  
1050 for ITMSn.

1051

### 1052 *Peptide/protein database searching*

1053 Mass spectra were searched using Proteome Discoverer 2.2 using the built-in SEQUEST  
1054 search algorithm. Three FASTA databases were searched: Uniprot Swiss-Prot *Mus*  
1055 *musculus* (taxon ID 10090, downloaded January 2017), a custom concatenated database  
1056 containing proteome data for all 15 bacteria in the reconstituted SIC (Fig. 3B), and a  
1057 database containing common preparatory contaminants. Target-decoy searching at both  
1058 the peptide and protein level was employed with a strict false discovery-rate cutoff of  
1059 0.05 using the Percolator algorithm built into Proteome Discoverer 2.2. Enzyme  
1060 specificity was set to tryptic, with static peptide modifications set to  
1061 carbamidomethylation (+57.0214 Da). Dynamic modifications were set to oxidation  
1062 (+15.995 Da) and N-terminal protein acetylation (+42.011 Da). Only high-confidence  
1063 proteins ( $q < 0.01$ ) were used for analysis.


1064

### 1065 *Proteome analysis*

1066 Custom MATLAB R2018a (MathWorks) scripts were used to analyze protein  
1067 abundances. *M. musculus* analyses were restricted to proteins that were 10 times more  
1068 abundant in germ-free, humanized, or SIC-colonized mice samples than in any *in vitro*

1069 bacterial cultures in our dataset. Similarly, *B. fragilis* and *B. producta* proteome analyses  
1070 were restricted to proteins that were 10 times more abundant in humanized mice, SIC-  
1071 colonized mice, and SIC samples than in germ-free mice.

1072 **Figure Legends**



1073

1074 **Figure 1: High-throughput cultivation of feces from humanized mice yields stable,**  
 1075 **complex and reproducible microbial communities.**

1076 A) Experimental setup. Germ-free mice colonized with feces from a single human  
 1077 donor (“humanized”) were fed a SD or an MD and treated with ciprofloxacin for  
 1078 5 days. Inocula from two mice on each diet were taken on four days (0, 1, 5, 14)

1079 before, during, and after treatment, and were inoculated into anaerobic batch  
1080 culture and passaged with dilution every 48 h to derive SICs. Sixteen samples (2  
1081 diets, 2 mice, 4 time points during ciprofloxacin treatment) were inoculated into  
1082 4 media (BHI, TYG, GAM, and YCFA) in triplicate.

1083 B) Ciprofloxacin elicits large changes in microbiota composition at the phylum level  
1084 *in vivo*. Each time point has two bars corresponding to the two mice in each  
1085 group.

1086 C) Diet alters the trajectory of microbiota reorganization during ciprofloxacin  
1087 treatment *in vivo*. PCoA of community composition of the fecal inocula in (B)  
1088 using unweighted Unifrac distance computed on all *in vivo* and *in vitro* samples  
1089 at the ASV level.

1090 D) *In vitro* passaging produces stable and complex SICs. Family-level compositions  
1091 of an example SIC derived from the fecal inoculum of pre-treatment MD mouse 1  
1092 during 16 rounds of *in vitro* passaging in BHI.


1093 E) *In vitro* passaging can produce an SIC that resembles the fecal inoculum. Mean  
1094 family-level  $\log_{10}$ (relative abundance) of passages 4-16 for the SIC in (D) and the  
1095 fecal inoculum from which it originated. Families with relative abundance of 0  
1096 were set to  $10^{-4}$  for visualization.

1097 F) Colonization of germ-free mice with an SIC restores families overrepresented *in*  
1098 *vitro* back to levels similar to those in the humanized mice from which the SIC

1099 was derived. Comparison of the family-level  $\log_{10}$ (relative abundance) of a  
1100 humanized-mouse fecal inoculum and the mean family-level  $\log_{10}$ (relative  
1101 abundance) of ex-germ-free mice colonized with an SIC derived from the  
1102 humanized-mouse fecal inoculum (inoculum  $n=1$ , SIC-colonized  $n=3$ ). Families  
1103 with relative abundance of 0 were set to  $10^{-4}$  for visualization.

1104 G,H) *In vitro*-passaged SICs are highly reproducible. (G) ASV-level  $\log_{10}$ (relative  
1105 abundance) for two technical replicates of the SIC in (D) after 7 passages. ASVs  
1106 with relative abundance of 0 were set to  $10^{-4}$  for visualization. (H) Summary of  
1107 the reproducibility of the three replicates for the SIC in (D).  $R$  and  $p$  were  
1108 computed using only ASVs present in both samples. Also shown is the  
1109 percentage of ASVs that are present in both replicates at  $>0.1\%$  abundance  
1110 (“shared”), with the total number of ASVs in parenthesis.

1111 I,J) SICs can be grown in larger volumes and can be frozen and revived without  
1112 affecting composition. ASV-level  $\log_{10}$ (relative abundance) values for the SIC in  
1113 (D) after 7 passages were compared with the same SIC grown for one passage in  
1114 a larger vessel without shaking (I), and after freezing with 25% glycerol at  $-80\text{ }^{\circ}\text{C}$   
1115 and reviving for one passage (J).  $R$  and  $p$  were computed using only ASVs  
1116 present in both samples. ASVs with relative abundance of zero were set to  $10^{-4}$   
1117 for visualization.



1118

1119 **Figure 2: SIC composition is determined by inoculum and media, and is predictive of**  
 1120 **yield and growth rate.**

1121 A) Medium and inoculum determine the final composition of passaged SICs. The 7<sup>th</sup>  
 1122 passage of all 192 SICs in a PCoA of SIC composition using unweighted Unifrac  
 1123 distance computed on all *in vivo* and *in vitro* samples at the ASV level. Samples  
 1124 are separated by media, with colors and shapes representing the timepoint  
 1125 during ciprofloxacin treatment and diet, respectively, in the mice from which the  
 1126 inocula were taken. Symbols are the centroid of three replicates, with lines

1127 connecting the replicates to the centroid. Original fecal inocula are plotted in  
1128 light colors (same data as in Fig. 1C).

1129 B) Most steady-state SICs are similar to the fecal samples from which they were  
1130 derived. Weighted Unifrac distance of the 7<sup>th</sup> passage of each SIC to the  
1131 corresponding fecal inoculum. Colored circles, mean distance for each medium;  
1132 individual SICs in gray. Error bars, standard deviations (SD);  $n=48$ . Dashed line,  
1133 mean distance between fecal samples.

1134 C) SICs derived from feces at the peak of treatment *in vivo* are most distinct from the  
1135 composition of their inoculum. Weighted Unifrac distance of the 7<sup>th</sup> passage in  
1136 BHI of each SIC to their fecal inoculum. Symbols and line are as in (B);  $n=12$ .

1137 D) SIC diversity correlates with inoculum diversity in most media. Richness  
1138 (number of ASVs in rarefied data) was compared for the 7<sup>th</sup> passage of each SIC  
1139 and the corresponding fecal inocula and separated and colored/shaped as in (A).  
1140  $R$  and  $p$  were calculated from all samples in a given medium;  $n=48$ .

1141 E) SIC yield scales with diversity. Mean OD of SICs after 20 h of growth in BHI  
1142 passages 3-7 increases with increasing richness (number of ASVs in rarefied data)  
1143 in passage 7.  $R$ , Pearson correlation coefficient;  $n=48$ .


1144 F) Maximum growth rate is correlated with the abundance of fast-growing families.  
1145 Maximum growth rate was calculated from growth curves during the 7<sup>th</sup> passage  
1146 and BHI-passaged SICs were classified based on the relative abundance of

1147 Enterobacteriaceae and Enterococcaceae ( $f_{\text{Enteroc}})$ . Black circles, mean maximum  
1148 growth rate for each group ( $n=11$  for  $f_{\text{Enteroc}} < 20\%$  and  $n=37$  for  $f_{\text{Enteroc}} > 20\%$ ); error  
1149 bars, SD. Individual data points are plotted in gray.  $p$ -value is from a Student's  
1150 two-sided  $t$ -test between the two groups.

1151 G) SIC yield scales with the presence of fast-growing families.  $\text{OD}_{20\text{h}}$  is as in (E).  
1152 SICs with  $>20\%$  Enterococcaceae but  $<20\%$  Enterobacteriaceae are labeled as  
1153  $f_{\text{Enterococcaceae}} > 20\%$ . Black circles, mean maximum growth rate for each group ( $n=5$  for  
1154  $f_{\text{Enteroc}} < 20\%$ ,  $n=15$  for  $f_{\text{Enterococcaceae}} > 20\%$ , and  $n=8$  for  $f_{\text{Enteroc}} > 20\%$ ); error bars, SD.  
1155 Individual data points are plotted in gray.  $p$ -values are from a Student's two-  
1156 sided  $t$ -test between each pairwise comparison.

1157 H-I) Changes in SIC composition during passaging are reflected in altered SIC  
1158 growth. Percentage of Enterococcaceae (H) and maximum growth rate (I) for  
1159 three technical replicates (i-iii) of the SIC derived from SD mouse 2 during  
1160 residual treatment passaged in YCFA. The increase in maximum growth rate and  
1161 blooming of the Enterococcaceae occur concurrently in two of the replicates.






1162

1163 **Figure 3: Community growth can be partially reconstituted from isolates.**

- 1164 A) Experimental setup. Fifteen strains representing distinct species were isolated  
1165 from an SIC passaged in BHI derived from an MD mouse pre-treatment fecal  
1166 sample (parent SIC). The 15 strains, or the closest relative reference strains, were  
1167 mixed and co-cultured (reconstituted and reference SIC, respectively).
- 1168 B) Isolated strains represent 69% of the composition of the parent SIC. Left: relative  
1169 abundances of the 15 ASVs in the parent SIC. Right: normalized relative  
1170 abundances of the non-isolated ASVs. Multiple strains map to a single ASV.
- 1171 C-E) Isolates display a range of growth behaviors. Mean values of maximum growth  
1172 rate (C), lag time (D), and OD after 48 h of growth (E) of the 15 isolates in (B).  
1173 Error bars, standard deviations (SD);  $n=6$ .
- 1174 F-G) Parent SIC growth characteristics are partially recapitulated by reconstituted  
1175 and reference SICs. Maximum growth rate (F) and OD after 48 h of growth (G) of  
1176 the parent SIC in (B), and the reconstituted and reference SICs. Colored circles  
1177 and error bars represent mean values and SD;  $n=4$ .  $p$ -values are from a Student's  
1178 two-sided  $t$ -test between each pairwise comparison; ns: not significant.
- 1179 H) Yields (OD after 48 h of growth in BHI) of isolates in (C-E) and corresponding  
1180 reference strains are mostly correlated. Isolate abbreviations are defined in (C).
- 1181 I) Relative abundances of ASVs in reconstituted (left) or reference (right) SICs  
1182 during three passages in BHI. Multiple strains can be mapped to a single ASV.

1183 J,K) Reconstituted (J) and reference (K) SICs converge to compositions with relative  
1184 abundances similar to that of the parent SIC. Data are mean  $\log_{10}$ (relative  
1185 abundance) of ASVs, normalized to the total relative abundance of those ASVs  
1186 within the reconstituted or parent SIC. Error bars, SD;  $n=4$ . *R*, Pearson correlation  
1187 coefficient.

1188 L,M) Isolate growth behaviors do not correlate with their abundances in  
1189 reconstituted SIC. Mean  $\log_{10}$ (relative abundance) of ASVs corresponding to  
1190 isolates in the 3rd passage of reconstituted SIC is uncorrelated with the OD of the  
1191 isolates after 48 h of growth (L) or maximum growth rate of those strains in  
1192 isolation (M). Error bars, SD;  $n=4$  for relative abundances,  $n=6$  for OD and  
1193 maximum growth rate. *R*, Pearson correlation coefficient. Where multiple strains  
1194 map to a single ASV, the relative abundance of the ASV value is used for all  
1195 strains that map to that ASV.



1196

1197 **Figure 4: SIC response to ciprofloxacin can be predicted from exposure history and**  
 1198 **individual member sensitivities.**


1199 A) Experimental setup. An SIC passed in BHI from pre-treatment humanized mouse  
 1200 fecal inoculum (Pre-SD) was revived after freezing and passed twice in BHI. The  
 1201 SIC was then passed in ciprofloxacin three times.

1202 B) Pre-SD SIC yield and growth rate decrease with increasing concentrations of  
 1203 ciprofloxacin. OD was measured after 48 h of growth with ciprofloxacin. Lines,  
 1204 means of triplicate growth curves; error bars, standard deviations (SD).

1205 C) Pre-SD SIC shows little adaptation to ciprofloxacin. Maximum growth rate decreases  
 1206 or remains approximately constant across three passages in ciprofloxacin. Symbols  
 1207 are as in (B).

- 1208 D) Richness (number of ASVs in rarefied data) of Pre-SD SIC decreases during  
1209 ciprofloxacin. Data are means of two technical replicates.
- 1210 E) Ciprofloxacin treatment *in vitro* selects for a few families. Family-level composition  
1211 of the Pre community across passages in ciprofloxacin. The limit of detection was  
1212 estimated at  $10^{-3}$ . Data are means of two technical replicates.
- 1213 F) Growth of ASVs in the Pre-SD SIC under ciprofloxacin treatment can be predicted  
1214 by their sensitivity in isolation. Fractional-abundance changes of ASVs  
1215 corresponding to the 15 isolates in Fig. 3A were computed after one passage in 2  
1216  $\mu\text{g}/\text{mL}$  ciprofloxacin. MICs were calculated during growth in isolation in BHI (Table  
1217 S1).

1218



1219

1220 **Figure 5: Ciprofloxacin treatment *in vitro* reproduces features of *in vivo* dynamics at**

1221 **multiple taxonomic levels.**

- 1222 A) Changes in family-level abundances during ciprofloxacin treatment *in vivo* can  
1223 be predicted by strain-level sensitivities *in vitro*. Fractional changes were  
1224 computed as the ratio of residual and pre-treatment time-point abundances *in*  
1225 *vivo*. MIC is the mean value across strains in a given family determined from  
1226 growth in isolation in BHI (Table S1).
- 1227 B) Experimental setup mimicking *in vivo* transient treatment. An SIC passaged in  
1228 BHI from pre-treatment humanized mouse fecal inoculum (Pre-SD) was revived  
1229 after freezing and passaged twice in BHI. The SIC was then passaged in  
1230 ciprofloxacin three times (i,ii,iii); in ciprofloxacin once and then twice without the  
1231 drug (i,iv,v); or re-exposed to the drug after one round of recovery (i,iv,vi).
- 1232 C) Pre-SD SIC growth rate can recover to levels similar to values before treatment at  
1233 low concentrations. Maximum growth rate was calculated across ciprofloxacin  
1234 concentrations during one round of antibiotic treatment and two rounds of  
1235 recovery. Lines, mean of three technical replicates; error bars, standard  
1236 deviations (SD).
- 1237 D) Richness of Pre-SD SIC recovered only partially after removal of ciprofloxacin  
1238 (green) versus continuous exposure (blue, same data as Fig. 4D). Data are the  
1239 mean of two replicates.
- 1240 E) The Pre-SD SIC was further remodeled after removal of low-dose antibiotic  
1241 treatment. Bray-Curtis dissimilarity index of SICs was calculated after the third

1242 passage in ciprofloxacin (blue) or after two rounds of recovery (green) with  
1243 respect to their untreated composition. Data are the mean of two technical  
1244 replicates.

1245 F) Some families, like the Erysipelotrichaceae and Ruminococcaceae, can recover  
1246 after transient ciprofloxacin treatment. Data are the mean  $\log_{10}$ (relative  
1247 abundance) of two replicates during one round of ciprofloxacin treatment and  
1248 two rounds of recovery at the family level.

1249 G) Ciprofloxacin-induced changes to family-level abundances in SD mice *in vivo*  
1250 resemble changes *in vitro* in (F). Data are the mean  $\log_{10}$ (relative abundance) of  
1251 two mice at the family level.


1252 H) Most families display similar qualitative abundance changes *in vivo* and *in vitro*.  
1253 Split boxes denote either different responses across diets *in vivo* (asterisk denotes  
1254 the response in MD mice, Fig. S9E) or across ciprofloxacin doses *in vitro*.

1255 I) *Bacteroides* dynamics *in vivo* consist of *B. vulgatus* dominance during treatment  
1256 and the recovery of several species after treatment. Data are the mean  
1257  $\log_{10}$ (relative abundance) of two SD mice at the ASV level: *Bacteroides ovatus* (Bo),  
1258 *B. vulgatus* (Bv), *B. uniformis* (Bu), *B. caccae* (Bc), *B. intestinalis* (Bi), *B. fragilis* (Bf),  
1259 and *B. thetaiotaomicron* (Bt). Other *Bacteroides* are shown in shades of grey.

1260 J,K) *Bacteroides* survival and recovery *in vivo* can be respectively explained by  
1261 resistance and resilience characteristics of the Pre-SD SIC *in vitro* during



1262 continuous treatment (J) or one round of treatment followed by two rounds of  
1263 recovery (K). Data are the mean  $\log_{10}$ (relative abundance) of two replicates  
1264 during one round of ciprofloxacin treatment and two rounds of recovery at  
1265 the ASV level. Thick lines highlight *Bacteroides* ASVs that show resistance (J)  
1266 or resilience (K) at the highest concentration that they display the behavior.



1267

1268 **Figure 6: Pre-exposure of the gut microbiota to ciprofloxacin *in vivo* results in**

1269 **functional differences *in vitro*.**

1270 A) Experimental setup for *in vitro* challenge with *S. Typhimurium*. SICs passaged in

1271 BHI from pre-, peak, residual, and post-treatment humanized mouse fecal

1272 inocula were revived after freezing and passaged twice in BHI. SICs were mixed  
1273 with *S. Typhimurium* and *S. Typhimurium* levels were quantified after 48 h of  
1274 growth.


1275 B) SICs derived from mice treated with ciprofloxacin are more susceptible to *S.*  
1276 *Typhimurium*. Colonies of *S. Typhimurium* SL1344 after 48 h of growth with  
1277 SICs diluted 1:10<sup>4</sup> and grown aerobically on LB+streptomycin.

1278 C) Single-cell quantification of mCherry-tagged *S. Typhimurium* 14028s after co-  
1279 culture with SICs derived from pre- and residual-treatment mice fecal inocula. *p*-  
1280 value is from a Student's two-sided *t*-test; *n*=3.

1281 D) Experimental setup for *in vitro* antibiotic treatment of a pre-exposed SIC. An SIC  
1282 passaged in BHI from residual treatment humanized mouse fecal inoculum (Res-  
1283 SD) was revived after freezing and passaged twice in BHI. The SIC was passaged  
1284 in ciprofloxacin three times (i,ii,iii) or in ciprofloxacin once and then twice  
1285 without the drug (i,iv,v).

1286 E) In contrast to the Pre-SD SIC (Fig. 4B), the yield and of Res-SD SIC is virtually  
1287 unaffected by ciprofloxacin, although the growth rate decreases with  
1288 concentration. OD was measured after 48 h of growth with ciprofloxacin. Lines,  
1289 means of triplicate growth curves; error bars, standard deviations (SD).

- 1290 F) Richness (number of ASVs in rarefied data) of Pre-SD SIC remains constant  
1291 during continuous ciprofloxacin treatment. Data are means of two technical  
1292 replicates.
- 1293 G) Bacteroidaceae and Lachnospiraceae dominate during three rounds of  
1294 ciprofloxacin treatment of the Res-SD SIC. Data are the mean of family-level  
1295 abundances across two technical replicates.
- 1296 H) Enterococcaceae can recover after one round of ciprofloxacin treatment in the  
1297 Res-SD SIC. Data are the mean of two replicates.
- 1298 I) Res-SD SIC diversity can recover after ciprofloxacin removal. The Bray-Curtis  
1299 dissimilarity index of SICs at the third passage in ciprofloxacin (blue) or after  
1300 two rounds of recovery (green), compared to their untreated compositions. Data  
1301 are the mean of two replicates.
- 1302 G,H) Bacteroidaceae are remodeled in the Res-SD SIC during and after ciprofloxacin  
1303 treatment, with *B. vulgatus* as the only member to generally survive. Relative  
1304 abundances of *Bacteroides* species in the Res-SD SIC during continuous  
1305 ciprofloxacin treatment (G) or after one round of treatment followed by two  
1306 rounds of recovery (H).



1307

1308 **Figure 7: Batch culturing of human stool leads to stable and complex SICs.**

- 1309 A) *In vitro* passaging of stool samples from three healthy human donors in BHI  
1310 produced stable, complex SICs. Family-level composition; each passage was 48 h.  
1311 Colors corresponding to individual families are as in (B).
- 1312 B) *In vitro* passaging of stool samples leads to SICs that maintain many families  
1313 from the fecal microbiota. Mean relative abundance of three technical replicates  
1314 for each inoculum and corresponding 7<sup>th</sup> passage SIC in (A) (left) and all  
1315 humanized mice SICs (right). Only families with mean relative abundance >0.1%  
1316 are shown; undetectable taxa are shown in grey. Boxes highlight families  
1317 common to all SICs (orange), present in all human donor SICs but  
1318 underrepresented in humanized mice SICs (pink), and exclusive to all human  
1319 donor SICs (red).
- 1320 C) Passaging in BHI preserves the beta diversity of human stool inocula. PCoA was  
1321 computed with unweighted Unifrac distances using all 192 passaged SICs  
1322 inoculated with humanized mouse samples in Fig. 2A and the SICs in (A). Colors  
1323 and shapes are as in (C). Symbols represent the centroid of three replicates; lines  
1324 connect replicates to the centroid. SICs from humanized mice are shown in colors  
1325 in smaller dots in the same colors as in Fig. 1G and the humanized mice fecal  
1326 samples are shown in gray.
- 1327 D) Human stool-derived SICs are as similar to their inocula as humanized mice-  
1328 derived SICs, based on weighted Unifrac distances between steady-state SICs

1329 and their fecal inocula. SICs derived from humanized mice passaged in BHI or  
1330 YCFA are shown for comparison (data from Fig. 2B). Colored circles are the  
1331 mean of SICs ( $n=48$  for BHI and YCFA humanized mouse SICs and  $n=3$  for BHI  
1332 human donor SICs). Error bars, standard deviations. Individual data points are  
1333 shown in gray.

1334 **References**

1335

1336 Adamowicz, E.M., Flynn, J., Hunter, R.C., and Harcombe, W.R. (2018). Cross-feeding  
1337 modulates antibiotic tolerance in bacterial communities. *ISME J*.

1338 Aranda-Díaz, A., Obadia, B., Thomsen, T., Hallberg, Z.F., Güvener, Z.T., Ludington,  
1339 W.B., and Huang, K.C. (2019). Bacterial interspecies interactions modulate pH-mediated  
1340 antibiotic tolerance in a model gut microbiota. *BioRxiv*.

1341 Auchtung, J.M., Robinson, C.D., Farrell, K., and Britton, R.A. (2016). MiniBioReactor  
1342 Arrays (MBRAs) as a Tool for Studying *C. difficile* Physiology in the Presence of a  
1343 Complex Community. *Methods Mol Biol* 1476, 235-258.

1344 Baev, M.V., Baev, D., Radek, A.J., and Campbell, J.W. (2006). Growth of *Escherichia coli*  
1345 MG1655 on LB medium: determining metabolic strategy with transcriptional  
1346 microarrays. *Appl Microbiol Biotechnol* 71, 323-328.

1347 Barroso-Batista, J., Pedro, M.F., Sales-Dias, J., Pinto, C.J.G., Thompson, J.A., Pereira, H.,  
1348 Demengeot, J., Gordo, I., and Xavier, K.B. (2020). Specific Eco-evolutionary Contexts in  
1349 the Mouse Gut Reveal *Escherichia coli* Metabolic Versatility. *Curr Biol* 30, 1049-1062  
1350 e1047.

1351 Barthel, M., Hapfelmeier, S., Quintanilla-Martinez, L., Kremer, M., Rohde, M., Hogardt,  
1352 M., Pfeffer, K., Russmann, H., and Hardt, W.D. (2003). Pretreatment of mice with



1353 streptomycin provides a *Salmonella enterica* serovar Typhimurium colitis model that  
1354 allows analysis of both pathogen and host. *Infect Immun* 71, 2839-2858.

1355 Becker, N., Kunath, J., Loh, G., and Blaut, M. (2011). Human intestinal microbiota:  
1356 characterization of a simplified and stable gnotobiotic rat model. *Gut Microbes* 2, 25-33.

1357 Browne, H.P., Forster, S.C., Anonye, B.O., Kumar, N., Neville, B.A., Stares, M.D.,  
1358 Goulding, D., and Lawley, T.D. (2016). Culturing of 'unculturable' human microbiota  
1359 reveals novel taxa and extensive sporulation. *Nature* 533, 543-546.

1360 Callahan, B.J., McMurdie, P.J., Rosen, M.J., Han, A.W., Johnson, A.J., and Holmes, S.P.  
1361 (2016). DADA2: High-resolution sample inference from Illumina amplicon data. *Nat*  
1362 *Methods* 13, 581-583.

1363 Cammarota, G., Ianiro, G., Tilg, H., Rajilic-Stojanovic, M., Kump, P., Satokari, R., Sokol,  
1364 H., Arkkila, P., Pintus, C., Hart, A., *et al.* (2017). European consensus conference on  
1365 faecal microbiota transplantation in clinical practice. *Gut* 66, 569-580.

1366 Caporaso, J.G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F.D., Costello, E.K.,  
1367 Fierer, N., Pena, A.G., Goodrich, J.K., Gordon, J.I., *et al.* (2010). QIIME allows analysis of  
1368 high-throughput community sequencing data. *Nat Methods* 7, 335-336.

1369 Carman, R.J., Simon, M.A., Fernandez, H., Miller, M.A., and Bartholomew, M.J. (2004).  
1370 Ciprofloxacin at low levels disrupts colonization resistance of human fecal microflora  
1371 growing in chemostats. *Regul Toxicol Pharmacol* 40, 319-326.

1372 Cho, I., Yamanishi, S., Cox, L., Methe, B.A., Zavadil, J., Li, K., Gao, Z., Mahana, D., Raju,  
1373 K., Teitler, I., *et al.* (2012). Antibiotics in early life alter the murine colonic microbiome  
1374 and adiposity. *Nature* *488*, 621-626.

1375 Cox, L.M., Yamanishi, S., Sohn, J., Alekseyenko, A.V., Leung, J.M., Cho, I., Kim, S.G., Li,  
1376 H., Gao, Z., Mahana, D., *et al.* (2014). Altering the intestinal microbiota during a critical  
1377 developmental window has lasting metabolic consequences. *Cell* *158*, 705-721.

1378 de Vos, M.G.J., Zagorski, M., McNally, A., and Bollenbach, T. (2017). Interaction  
1379 networks, ecological stability, and collective antibiotic tolerance in polymicrobial  
1380 infections. *Proc Natl Acad Sci U S A* *114*, 10666-10671.

1381 Del Monte-Luna, P., Brook, B.W., Zetina-Rejón, M.J., and Cruz-Escalona, V.H. (2004).  
1382 The carrying capacity of ecosystems. *Global Ecology and Biogeography* *13*, 485-495.

1383 Dethlefsen, L., and Relman, D.A. (2011). Incomplete recovery and individualized  
1384 responses of the human distal gut microbiota to repeated antibiotic perturbation. *Proc*  
1385 *Natl Acad Sci U S A* *108 Suppl 1*, 4554-4561.

1386 Doorduyn, Y., Van Den Brandhof, W.E., Van Duynhoven, Y.T., Wannet, W.J., and Van  
1387 Pelt, W. (2006). Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and  
1388 non-DT104) infections in The Netherlands: predominant roles for raw eggs in  
1389 Enteritidis and sandboxes in Typhimurium infections. *Epidemiol Infect* *134*, 617-626.

1390 Drekonja, D., Reich, J., Gezahegn, S., Greer, N., Shaukat, A., MacDonald, R., Rutks, I.,  
1391 and Wilt, T.J. (2015). Fecal Microbiota Transplantation for *Clostridium difficile*  
1392 Infection: A Systematic Review. *Ann Intern Med* 162, 630-638.

1393 Faith, J.J., McNulty, N.P., Rey, F.E., and Gordon, J.I. (2011). Predicting a human gut  
1394 microbiota's response to diet in gnotobiotic mice. *Science* 333, 101-104.

1395 Frohlich, E.E., Farzi, A., Mayerhofer, R., Reichmann, F., Jacan, A., Wagner, B., Zinser, E.,  
1396 Bordag, N., Magnes, C., Frohlich, E., *et al.* (2016). Cognitive impairment by antibiotic-  
1397 induced gut dysbiosis: Analysis of gut microbiota-brain communication. *Brain Behav*  
1398 *Immun* 56, 140-155.

1399 Goldford, J.E., Lu, N., Bajic, D., Estrela, S., Tikhonov, M., Sanchez-Gorostiaga, A., Segre,  
1400 D., Mehta, P., and Sanchez, A. (2018). Emergent simplicity in microbial community  
1401 assembly. *Science* 361, 469-474.

1402 Gutierrez, N., and Garrido, D. (2019). Species Deletions from Microbiome Consortia  
1403 Reveal Key Metabolic Interactions between Gut Microbes. *mSystems* 4.

1404 Hooper, L.V., Littman, D.R., and Macpherson, A.J. (2012). Interactions between the  
1405 microbiota and the immune system. *Science* 336, 1268-1273.

1406 Hwang, I., Park, Y.J., Kim, Y.R., Kim, Y.N., Ka, S., Lee, H.Y., Seong, J.K., Seok, Y.J., and  
1407 Kim, J.B. (2015). Alteration of gut microbiota by vancomycin and bacitracin improves  
1408 insulin resistance via glucagon-like peptide 1 in diet-induced obesity. *FASEB J* 29, 2397-  
1409 2411.

1410 Ivanov, II, Frutos Rde, L., Manel, N., Yoshinaga, K., Rifkin, D.B., Sartor, R.B., Finlay,  
1411 B.B., and Littman, D.R. (2008). Specific microbiota direct the differentiation of IL-17-  
1412 producing T-helper cells in the mucosa of the small intestine. *Cell Host Microbe* 4, 337-  
1413 349.

1414 Johansson, M.E., Jakobsson, H.E., Holmen-Larsson, J., Schutte, A., Ermund, A.,  
1415 Rodriguez-Pineiro, A.M., Arike, L., Wising, C., Svensson, F., Backhed, F., *et al.* (2015).  
1416 Normalization of Host Intestinal Mucus Layers Requires Long-Term Microbial  
1417 Colonization. *Cell Host Microbe* 18, 582-592.

1418 Kashyap, P.C., Marcobal, A., Ursell, L.K., Larauche, M., Duboc, H., Earle, K.A.,  
1419 Sonnenburg, E.D., Ferreyra, J.A., Higginbottom, S.K., Million, M., *et al.* (2013). Complex  
1420 interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice.  
1421 *Gastroenterology* 144, 967-977.

1422 Kehe, J., Kulesa, A., Ortiz, A., Ackerman, C.M., Thakku, S.G., Sellers, D., Kuehn, S.,  
1423 Gore, J., Friedman, J., and Blainey, P.C. (2019). Massively parallel screening of synthetic  
1424 microbial communities. *Proc Natl Acad Sci U S A* 116, 12804-12809.

1425 Khoruts, A., and Weingarden, A.R. (2014). Emergence of fecal microbiota  
1426 transplantation as an approach to repair disrupted microbial gut ecology. *Immunol Lett*  
1427 162, 77-81.

1428 Lawley, T.D., Bouley, D.M., Hoy, Y.E., Gerke, C., Relman, D.A., and Monack, D.M.  
1429 (2008). Host transmission of *Salmonella enterica* serovar Typhimurium is controlled by  
1430 virulence factors and indigenous intestinal microbiota. *Infect Immun* 76, 403-416.

1431 Le Bastard, Q., Ward, T., Sidiropoulos, D., Hillmann, B.M., Chun, C.L., Sadowsky, M.J.,  
1432 Knights, D., and Montassier, E. (2018). Fecal microbiota transplantation reverses  
1433 antibiotic and chemotherapy-induced gut dysbiosis in mice. *Sci Rep* 8, 6219.

1434 Lozupone, C., and Knight, R. (2005). UniFrac: a new phylogenetic method for  
1435 comparing microbial communities. *Appl Environ Microbiol* 71, 8228-8235.

1436 Lozupone, C.A., Hamady, M., Kelley, S.T., and Knight, R. (2007). Quantitative and  
1437 qualitative beta diversity measures lead to different insights into factors that structure  
1438 microbial communities. *Appl Environ Microbiol* 73, 1576-1585.

1439 Macfarlane, G.T., Macfarlane, S., and Gibson, G.R. (1998). Validation of a Three-Stage  
1440 Compound Continuous Culture System for Investigating the Effect of Retention Time  
1441 on the Ecology and Metabolism of Bacteria in the Human Colon. *Microb Ecol* 35, 180-  
1442 187.

1443 Mark Welch, J.L., Hasegawa, Y., McNulty, N.P., Gordon, J.I., and Borisy, G.G. (2017).  
1444 Spatial organization of a model 15-member human gut microbiota established in  
1445 gnotobiotic mice. *Proc Natl Acad Sci U S A* 114, E9105-E9114.

1446 Mayer, E.A., Knight, R., Mazmanian, S.K., Cryan, J.F., and Tillisch, K. (2014). Gut  
1447 microbes and the brain: paradigm shift in neuroscience. *J Neurosci* 34, 15490-15496.

1448 Minekus, M., Smeets-Peeters, M., Bernalier, A., Marol-Bonnin, S., Havenaar, R.,  
1449 Marteau, P., Alric, M., Fonty, G., and Huis in't Veld, J.H. (1999). A computer-controlled  
1450 system to simulate conditions of the large intestine with peristaltic mixing, water  
1451 absorption and absorption of fermentation products. *Appl Microbiol Biotechnol* 53, 108-  
1452 114.

1453 Ng, K.M., Aranda-Diaz, A., Tropini, C., Frankel, M.R., Van Treuren, W.W., O'Laughlin,  
1454 C., Merrill, B.D., Yu, F.B., Pruss, K.M., Oliveira, R.A., *et al.* (2019). Recovery of the gut  
1455 microbiota after antibiotics depends on host diet and environmental reservoirs. *Cell*  
1456 *Host Microbe*.

1457 Ng, K.M., Ferreyra, J.A., Higginbottom, S.K., Lynch, J.B., Kashyap, P.C., Gopinath, S.,  
1458 Naidu, N., Choudhury, B., Weimer, B.C., Monack, D.M., *et al.* (2013). Microbiota-  
1459 liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. *Nature*  
1460 502, 96-99.

1461 Nicoloff, H., and Andersson, D.I. (2016). Indirect resistance to several classes of  
1462 antibiotics in cocultures with resistant bacteria expressing antibiotic-modifying or -  
1463 degrading enzymes. *J Antimicrob Chemother* 71, 100-110.

1464 Pavia, A.T., Shipman, L.D., Wells, J.G., Puhr, N.D., Smith, J.D., McKinley, T.W., and  
1465 Tauxe, R.V. (1990). Epidemiologic evidence that prior antimicrobial exposure decreases  
1466 resistance to infection by antimicrobial-sensitive *Salmonella*. *J Infect Dis* 161, 255-260.

1467 Rettedal, E.A., Gumpert, H., and Sommer, M.O. (2014). Cultivation-based multiplex  
1468 phenotyping of human gut microbiota allows targeted recovery of previously  
1469 uncultured bacteria. *Nat Commun* 5, 4714.

1470 Reyes, A., Wu, M., McNulty, N.P., Rohwer, F.L., and Gordon, J.I. (2013). Gnotobiotic  
1471 mouse model of phage-bacterial host dynamics in the human gut. *Proc Natl Acad Sci U*  
1472 *S A* 110, 20236-20241.

1473 Rezzonico, E., Mestdagh, R., Delley, M., Combremont, S., Dumas, M.E., Holmes, E.,  
1474 Nicholson, J., and Bibiloni, R. (2011). Bacterial adaptation to the gut environment favors  
1475 successful colonization: microbial and metabonomic characterization of a simplified  
1476 microbiota mouse model. *Gut Microbes* 2, 307-318.

1477 Sanchez-Vizuite, P., Orgaz, B., Aymerich, S., Le Coq, D., and Briandet, R. (2015).  
1478 Pathogens protection against the action of disinfectants in multispecies biofilms. *Front*  
1479 *Microbiol* 6, 705.

1480 Schubert, A.M., Sinani, H., and Schloss, P.D. (2015). Antibiotic-Induced Alterations of  
1481 the Murine Gut Microbiota and Subsequent Effects on Colonization Resistance against  
1482 *Clostridium difficile*. *MBio* 6, e00974.

1483 Shi, H., Colavin, A., Lee, T.K., and Huang, K.C. (2017). Strain Library Imaging Protocol  
1484 for high-throughput, automated single-cell microscopy of large bacterial collections  
1485 arrayed on multiwell plates. *Nat Protoc* 12, 429-438.

1486 Sonnenburg, E.D., Smits, S.A., Tikhonov, M., Higginbottom, S.K., Wingreen, N.S., and  
1487 Sonnenburg, J.L. (2016). Diet-induced extinctions in the gut microbiota compound over  
1488 generations. *Nature* 529, 212-215.

1489 Sonnenburg, J.L., and Backhed, F. (2016). Diet-microbiota interactions as moderators of  
1490 human metabolism. *Nature* 535, 56-64.

1491 Stecher, B., Robbiani, R., Walker, A.W., Westendorf, A.M., Barthel, M., Kremer, M.,  
1492 Chaffron, S., Macpherson, A.J., Buer, J., Parkhill, J., *et al.* (2007). *Salmonella enterica*  
1493 serovar typhimurium exploits inflammation to compete with the intestinal microbiota.  
1494 *PLoS Biol* 5, 2177-2189.

1495 Tramontano, M., Andrejev, S., Pruteanu, M., Klunemann, M., Kuhn, M., Galardini, M.,  
1496 Jouhten, P., Zelezniak, A., Zeller, G., Bork, P., *et al.* (2018). Nutritional preferences of  
1497 human gut bacteria reveal their metabolic idiosyncrasies. *Nat Microbiol* 3, 514-522.

1498 Tropini, C., Moss, E.L., Merrill, B.D., Ng, K.M., Higginbottom, S.K., Casavant, E.P.,  
1499 Gonzalez, C.G., Fremin, B., Bouley, D.M., Elias, J.E., *et al.* (2018). Transient Osmotic  
1500 Perturbation Causes Long-Term Alteration to the Gut Microbiota. *Cell* 173, 1742-1754  
1501 e1717.

1502 Turnbaugh, P.J., Ridaura, V.K., Faith, J.J., Rey, F.E., Knight, R., and Gordon, J.I. (2009).  
1503 The effect of diet on the human gut microbiome: a metagenomic analysis in humanized  
1504 gnotobiotic mice. *Sci Transl Med* 1, 6ra14.



1505 Van de Wiele, T., Van den Abbeele, P., Ossieur, W., Possemiers, S., and Marzorati, M.  
1506 (2015). The Simulator of the Human Intestinal Microbial Ecosystem (SHIME((R))). In  
1507 The Impact of Food Bioactives on Health: in vitro and ex vivo models, K. Verhoeckx, P.  
1508 Cotter, I. Lopez-Exposito, C. Kleiveland, T. Lea, A. Mackie, T. Requena, D. Swiatecka,  
1509 and H. Wichers, eds. (Cham (CH)), pp. 305-317.

1510 Venturelli, O.S., Carr, A.C., Fisher, G., Hsu, R.H., Lau, R., Bowen, B.P., Hromada, S.,  
1511 Northen, T., and Arkin, A.P. (2018). Deciphering microbial interactions in synthetic  
1512 human gut microbiome communities. *Mol Syst Biol* 14, e8157.

1513 Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., and Goodman, A.L.  
1514 (2019). Separating host and microbiome contributions to drug pharmacokinetics and  
1515 toxicity. *Science* 363.

1516